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ABSTRACT 
Allogeneic stem cell transplantation (AHSCT) remains the only curative option for a 
number of patients with haematological malignancies. The interplay between a 
number of T cell subsets including Th1, Th2, Th17 and regulatory-T cells (Treg) has 
been linked to the establishment of graft-versus-leukaemia (GvL) as well as its 
deleterious counterpart graft-versus-host-disease (GvHD). A recent study defined a 
subset of memory antigen-specific CD8+T cells, with the ability to efflux cytotoxic 
drugs through the (ABC)-superfamily multidrug efflux complex. I hypothesized that a 
subset of CD4+T cells, capable of drug efflux through the MDR pump also exists. I 
confirmed the existence of CD4+T cells with „stem-like‟ properties, capable of rapidly 
effluxing Rhodamine123 as well as cytotoxic drugs such as daunorubicin. I confirmed 
that the effluxing properties of these cells are through ABCB1 and ABCC1 
transporters. Similar to their CD8 counterpart, the rhodamine-effluxing subset of 
CD4+T cells had a memory phenotype and was enriched within the CD161+T cell 
compartment. Lastly, using CMV and Flu as model antigens, I showed that viral-
specific memory CD4+T cells are enriched within the rhodamine-effluxing 
CD4+CD161+T cell population. Once I characterized these cells, I hypothesized that, 
through effluxing corticosteroids and other immunosuppressant drugs,CD161+CD4+ T 
cells may also play a role in acute GvHD. CD161+CD4+ T cells are precursors of 
Th17 cells. I demonstrated that, whereas Tregs are prone to apoptosis when exposed 
to corticosteroids, CD4+CD161+Th17 cells rapidly efflux and survive exposure to 
corticosteroids and other immunosuppressive drugs in vitro. Inhibition of the ABCB1 
and ABCC1 with inhibitors such as vinblastine induced apoptosis of this 
CD4+CD161+Th17 steroid-refractory T cell subset. I observed that patients with 
steroid-refractory GvHD had significantly higher frequencies of CD161+CD4+ T cells 
compared to patients with no or steroid-responsive GvHD. I also enumerated 
CD161+CD4+ T cells and Foxp3+T cells in the stem cell graft and donor lymphocytes 
and found an association between higher CD4+CD161+ and lower Foxp3+T cells 
frequencies and the risk of GvHD post-transplant. These data advance our 
understanding of potential mechanisms of steroid-refractory GvHD and have 
important implications for the development of novel therapeutic approaches for the 
treatment of this challenging group of patients. 
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CHAPTER 1. INTRODUCTION 
1.1 Allogeneic Stem Cell Transplantation 
Allogeneic Haematopoietic Stem Cell Transplantation (AHSCT) remains the only 
curative option for many malignant haematological conditions.  The development of 
reduced intensity conditioning regimens and improved supportive care have 
broadened the indications for the procedure and in Europe alone, over 24,000 stem 
cell transplants are currently performed each year(ESH-EBMT 2008).  In addition to 
the treatment of haematological malignancies, AHSCT is increasingly employed in a 
number of non-malignant conditions including inherited haemoglobinopathies, 
metabolic disorders and congenital immunodeficiency syndromes.  However, 
treatment of malignant haematological conditions remains the most common 
indication for AHSCT, where harnessing the powerful anti-tumour capacity of the 
donor immune system is the cornerstone of long term disease eradication and 
prevention of relapse. 
 
The success of AHSCT is influenced by a number of variables including the 
underlying condition, disease status, patient / donor age and importantly, the degree 
of HLA matching between donor and recipient(ESH-EBMT 2008;Ringden et al. 
2003).A number of complications hamper the beneficial effect of AHSCT and 
increase procedure related morbidity and mortality including infection, conditioning 
regimen toxicity and graft versus host disease (GvHD)(Gratwohl et al. 2005).    The 
control of these complications and other procedure-related complications, coupled 
with the ability to maximise immune mediated, graft-derived anti-tumour effect, are 
key to the further improvement of transplant outcome. 
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1.2 Graft versus Leukaemia and Graft versus Host Disease 
1.2.1 Historical overview 
The beneficial graft versus tumour / leukaemia effect (GVL) was observed in early 
murine experiments in the 1950s where it was first demonstrated that the eradication 
of leukaemia was possible(Barnes and Loutit 1957).  However this success was 
accompanied by a fatal, wasting diarrheal syndrome that would now be recognised 
as GvHD.  In contrast to the setting of solid organ transplantation, where the major 
concern is rejection of the donor organ by the recipient immune system, AHSCT 
reconstitutes an active, donor-derived immune system which, on the one hand, is 
able to recognise the recipient‟s residual leukaemia cells as foreign and eradicate 
them, and on the other, has the capacity to recognise the host tissues as foreign, 
resulting in immune attack of the recipient– GvHD.  Some of the most compelling 
evidence for the power of anti-leukaemia alloresponses comes from the efficacy of 
donor lymphocyte infusion (DLI), introduced into clinical practice in the early 1990s 
to enhance anti-leukaemia immune responses and treat post-transplant disease 
relapse(Deol and Lum 2010;Helg et al. 1998).  In addition, the ability of reduced 
intensity conditioned (non-myeloablative) transplants to eradicate haematological 
malignancy relies largely on immunologic GVL reactions.  
 
Both GvL and GvHD involve the recognition of minor histocompatibility antigens 
presented on the recipient‟s antigen presenting cells (APC), which accounts for the 
clinical overlap in GvL and GvHD.   
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The biological overlap in the immunological mechanisms at play in GvL and GvHD 
has been clearly demonstrated. Haematological disease relapse is more common in 
patients without any evidence of GvHD; conversely allograft T cell depletion results 
in reduced GvHD but increased relapse rate(Alyea 2008). Nevertheless there is 
experimental evidence that GvL and GvHD could be separated and a number of 
research groups are actively pursuing this goal.  
 
1.2.2 Clinical manifestation of acute GvHD 
The clinical syndrome of GvHD manifests as tissue injury mediated both by 
inflammatory cytokines and cytotoxic effector T cells.  The syndrome has been 
divided into two phases: acute, occurring earlier than 100 days post-allograft and 
chronic, occurring after 100 days.  Acute GvHD primarily affects the skin, liver and 
gastrointestinal tract, whereas chronic GvHD typically has a multisystem, 
(classically) autoimmune-syndrome pattern and may have a wider distribution of 
affected tissues (Table 1.1).  Temporal division of the two manifestations is however 
challenging.  Acute GvHD is not necessarily followed by the chronic form and 
conversely chronic GvHD can arise de novo without prior acute GvHD.  In addition 
late-onset GvHD with the clinical pattern of acute GvHD is recognised(Mielcarek et 
al. 2003).  These problems led to a working group consensus statement in 2005 
from the National Institutes of Health that proposed new criteria for diagnosis and 
classification of chronic GvHD for clinical trials. According to the consensus criteria, 
clinical manifestations, rather than time after transplantation, should be used in 
clinical trials to distinguish chronic GvHD from late acute GvHD, which includes 
persistent, recurrent, or late-onset acute GvHD(Filipovich et al. 2005). 
 
 
 Abdullah S. Alsuliman  PhD Thesis, 2013 
 
21 
 
Organ involved Acute  
GvHD 
Chronic  
GvHD 
 
Skin 
 
 
Maculopapular rash, 
ulceration 
 
Abnormal 
pigmentation, 
alopecia, sclerosis 
 
 
Upper 
gastrointestinal 
tract 
 
 
Nausea and 
vomiting 
 
Xerostomia, 
ulceration, 
oesophageal strictures 
 
 
Lower 
gastrointestinal 
tract 
 
 
Watery diarrhea 
(>500ml), abdominal 
pain, ileus 
 
 
Weight loss 
 
Liver 
 
 
Cholestatichyperbilir
ubinaemia 
 
Jaundice, 
transaminitis 
 
Eyes 
 
 
- 
Sicca syndrome, 
conjunctivitis 
 
Lungs 
 
- 
 
Obliterative 
bronchiolitis, 
restrictive defects, 
pleural effusions 
 
 
Bone marrow 
 
 
- 
 
Cytopaenias 
 
Musculoskeletal 
 
- 
 
Myositis, fasciitis, 
contractures 
 
Table ‎1.1: Clinical Patterns of Acute and Chronic GvHD 
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1.2.3 Target antigens for GvHD 
The most important antigens in the pathogenesis of GvHD are the human leukocyte 
antigens (HLA)(Ferrara et al. 2009).   These proteins are highly polymorphic and 
expressed on almost all nucleated cells in the body.  The degree of mismatch 
between donor and recipient HLA proteins is directly related to the risk of 
GvHD(ESH-EBMT 2008;Ferrara, Levine, Reddy, & Holler 2009).However GvHD still 
occurs in fully HLA-matched transplants, indicating the importance of other proteins, 
termed minor histocompatibility antigens (mHA) in driving the allo-immune T cell 
response.  In contrast to HLA molecules, mHAs may be expressed ubiquitously, 
such as HY and HA-3 or may exhibit tissue specificity such as HA-1 and HA-2, 
which are restricted to haematopoietic tissues(Loiseau et al. 2007). The potential 
exploitation of this tissue separation to extract useful GvL effect from unwanted 
GvHD is one avenue of current active research. 
 
1.2.4 Pathophysiology of acute GvHD 
Acute GvHD is initiated by massive cytokine storm, induced by the conditioning 
regimen itself.  Damaged host tissues produce pro-inflammatory cytokines and 
chemokines, resulting in APC activation and increased cross-presentation of 
polypeptide antigens to donor immune cells.  This may be further enhanced by the 
presence of infection, the underlying haematological malignancy itself and the 
systemic translocation of additional inflammatory stimuli across damaged 
mucosa(Pidala and Anasetti 2009;Xun et al. 1994).  These activated APCs then 
stimulate donor T cells to proliferate and produce large amounts of cytokines, 
particularly interferon-gamma (IFNγ), interleukin-2 (IL2) and tumour necrosis factor-
alpha (TNFα), which in turn promote the stimulation of cellular mediators including 
cytotoxic T lymphocytes (CTL) and natural killer (NK) cells.    
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These mediators destroy target tissues via cell lysis pathways such as Fas-Fas 
Ligand, perforin and granzyme, resulting in clinical GvHD(Hill et al. 1997;Jacobsohn 
et al. 2003;Mielcarek et al. 2003)(Figure 1.1). 
 
Figure ‎1.1: Pathophysiology of acute GvHD. Diagram shows the sequential 
development of acute GvHD and the involvement of cellular and soluble mediators. 
Adopted from Ferrara et al, Graft versus Host Disease, Lancet 2009. 
 
 
 Abdullah S. Alsuliman  PhD Thesis, 2013 
 
24 
1.2.5 Acute GvHD grading 
Grading criteria for acute GvHD have evolved over time. The first system was 
published by Glucksberg in mid-seventies (Glucksberg et al. 1974). These criteria 
measure the involvement of each organ and give an overall grading from I-IV. 
Nevertheless, a newer version of this system came in 1994, so-called modified 
Seattle Glucksberg criteria (Przepiorka et al. 1995)and it included the percentage of 
skin involvement and using a system known as the “rule of nines” the body surface 
area involvedcan be calculated (Hettiaratchy & Papini, 2004). The international bone 
marrow transplant registry (IBMTR) has also introduced another grading 
systemclassifying GvHD severity from A-D according the outcome of the transplant 
(Rowlings et al, 1997). While IBMTR grading criteria minimize bias in scoring by 
physicians, modified Seattle Glucksberg system was better in predicting survival. 
Nevertheless, there are no advantages for the one system over the other(Cahn et al, 
2005). 
 
1.2.6 GvHD prophylaxis and treatment 
Prophylaxis and treatment of acute GvHD consist of pharmacological agents to 
interrupt the cascade of inflammation .Prior to AHSCT, patients undergo preparative 
regimens aimed at eradicating residual cancer cells as well as suppressing recipients‟ 
immune system to allow the donor cells engraftment.  The calcineurin inhibitors (e.g. 
cyclosporine and tacrolimus) and methotrexate constitute the usual standard of care 
for prophylaxis. However, failure of prophylaxis regimens to suppress the undesired 
allo-reaction i.e. GvHD, necessitate prompt intervention. High dose corticosteroids 
are usually the front-line in the management of active GvHD.  A high proportion of 
patients however fail to respond to corticosteroids. Steroid-refractory GvHD and 
complications associated with immunosuppressive regimens continue to thwart the 
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success of AHSCT(Jacobsohn et al. 2003).Several interventions, such as mTOR 
inhibitors and mycophenolatemofetil (MMF), were employed in an effort to reverse 
steroid resistance(Dignan et al. 2012). Severe GvHD has a poor prognosis, with 
<25% 5 year survival for disease grade III or above despite maximum 
intervention(ESH-EBMT 2008;Jacobsohn et al. 2003).Harnessing the power of 
regulatory T cells for the improved control of GvHD and consequent reduction in 
transplant related morbidity and mortality is an enticing strategy, although to be a 
successful approach it will be essential to ensure that donor engraftment, anti-tumour 
allo-responses (GvL)and protection against infection are not adversely affected. 
 
1.3 T cell Biology and subsets 
T cells are fundamental in the adaptive immune response, mostly as a 
consequence of their huge diversity, in addition to their ability to produce a wide 
spectrum of cytokines. They belong to a group of cells known as lymphocytes. 
Generally, T cells originate in the bone marrow from a haematopoietic stem cell 
precursor (HSC). They then emigrate to the thymus where they undergo 
maturation, negative and positive selection and tolerance induction to self-
antigens, which help in identification and destruction of the self-reactive clones, 
thus maintaining immune tolerance(Abbas A.K. et al. 2007). 
 
Historically, these cells have been identified by the surface expression of CD3 in 
addition to the mutual expression of either TCR αβ or γδ. T cells with TCR αβ 
subunits are further characterized by the surface expression of CD4 and CD8, 
which differentiate the two major subsets of T cells, namely helper (Th) and 
cytotoxic (Tc) T cells, respectively. Additionally, according to their ability to produce 
specific cytokines, these two subsets can be categorized into Th1/Tc1, Th2/Tc2 
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and Th17/Tc17(Abbas A.K., Lichtman A.H., & Pillai 2007).  However, other T cell 
subsets, albeit in much smaller numbers, exist including γδ T cells, double negative 
(CD4- CD8-) and double positive (CD4+CD8+) T cells. 
  
1.3.1  Helper T cell subsets 
When naïve CD4+ helper T cells (Th) encounter their cognate antigens through 
TCR complex- MHC-II interaction, they tend to differentiate into effector phenotype. 
T-helper cells were classically subdivided into Th1 and Th2(Boyton and Altmann 
2002); however, the recent identification of IL-17-producing CD4+cells (Th17), and 
TGF-β-induced regulatory T cells (iTreg), has changed the dogma of Th 
classifications(Wan and Flavell 2009). The differentiation fate of these Th subsets 
is largely governed by a number of factors including the cytokine milieu during the 
differentiation process as well as their transcriptional factor network. Accordingly, 
these subsets can be distinguished by their cytokine production and their master 
transcriptional factor. Also, the affinity of their cognate antigen could have an 
influence on their lineage commitment(Boyton & Altmann 2002;Zhu and Paul 
2010).  Interestingly, although the commitment of each Th cell to one phenotype is 
absolute, a great degree of plasticity has been observed within these subsets as 
discussed later(Zhou et al. 2009). 
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Figure ‎1.2: CD4
+
 helper T cell subsets. This illustration shows the different T cell 
subsets, their lineage-specific transcriptional factors and cytokines.Adopted from O‟Shea 
et al, Science, 2010. 
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1.3.1.1 T helper type 1(Th1) 
The cytokine milieu in addition to the master transcriptional network can drive the 
differentiation and fate of T cells.   
Th1 cells are key players in the clearance of intracellular microorganisms (viruses 
and some bacteria), mostly through their ability to produce large amounts of IFNγ, 
which is considered as a major signature of this Th subset. Interleukin-12, 
produced by cells of the innate immune system, in addition to IFNγ, produced by T 
cells and NK cells, act as a positive feedback loop to induce polarization toward a 
Th1 phenotype. The transcriptional network controlling Th1 differentiation includes 
signalling transducer and activator transcription 1 and 4 (STAT1 and 4), as well as 
T box transcription factor (Tbet) (Zhou, Chong, & Littman 2009;Zhu & Paul 2010). 
 
1.3.1.2 T helper type 2(Th2) 
In contrast to Th1 cells, Th2 cells produce a wider range of immunomodulatory 
cytokines including interleukin-4 (IL-4), IL-5, IL-9, IL-13, and IL-25. During antigen 
recognition, the presence of IL-4 polarizes naïve CD4+ T cell differentiation towards 
Th2 cell fate. Additionally, this process results in the activation of STAT6. The 
action of both IL-4 and STAT6 consequently up-regulates GATA3, the master 
regulator for this subset‟s differentiation fate. The main role of this subset of T 
helper cells is protecting the body against parasitic infections such as helminths. It 
also plays a key role in allergic reactions(Zhu & Paul 2010). 
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1.3.1.3 T helper type 17(Th17) 
A role of interleukin 17 in the immune response has been known for some time(Kolls 
and Linden 2004); however it is only in the last few years, that IL-17-producing CD4+ 
T cells were defined as a new Th subset. This notion was supported by the fact that 
these cells could not produce cytokines of other Th lineages (IFN and IL-4), in 
addition to the requirement for a distinct set of cytokines to drive their differentiation 
including TGF-β, IL-6, IL-21 and IL-23 and most importantly the expression of their 
unique master transcription factor, retinoic acid-related orphan receptor 
(ROR)γt(Ivanov et al. 2006;Miossec et al. 2009). Polarization of Th17 cells with the 
aforementioned cytokines (IL-6, IL-21 and IL-23) activates STAT3,which in turn 
induces RORγt expression. Additionally, other transcriptional factors including the 
AP-1 family members, BFAT and Runx1, have been shown to be involved in the 
induction of the Th17 master regulator(Zhu & Paul 2010). Th17 cells mainly produce 
IL-17A, in addition to IL-17F, IL-21 and IL-22(Miossec, Korn, & Kuchroo 2009). They 
play an important role in expelling extracellular microorganisms e.g. fungi and 
bacteria(Weaver et al. 2006).Although phenotypically Th17 cells do not have specific 
characteristics; the origin of this subset has been proposed to be CD4+ CD161+ T 
cells (unlike Th1 and Th2 cells) (Cosmi et al. 2008). 
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1.3.2 CD161-expressing T cells 
Human CD161, also known as NKR-PA1, is made of disulfide-linked homodimer 
subunits and was originally identified on murine NK cells. In humans, the vast 
majority of NK cells express CD161, in contrast to only approximately one quarter of 
all T cells (TCR-αβ, -γδ and double negative)(Lanier et al. 1994a;Maggi et al. 2010). 
Two related ligands for CD161 have been recognized:Lectin-liketranscript1 (LTT1), 
expressed on activated APC and T cells, and proliferation-induced lymphocyte-
associated receptor (PILAR),expressed on T cells post-TCR engagement(Aldemir et 
al. 2005;Huarte et al. 2008). 
 
Generally, CD161-expressing CD4 and CD8 T cells reside within the memory T cell 
repertoire(Takahashi et al. 2006). However, a very small percentage of naïve 
CD161+CD4+ T cells were also identified in cord blood(Cosmi et al. 2008). Unlike 
CD4+ T cells which have intermediate expression of CD161, CD8+ T cells express 
CD161 at two levels: intermediate and high(Takahashi, Dejbakhsh-Jones, & Strober 
2006). Several reports have examined the origin and function of the CD8+ CD161hi 
population. CD8+ CD161hi T cells co-expressing IL-18Rα, were shown to have a 
chemo-effluxing, memory-like stem cell phenotype(Turtle et al. 2009). Likewise, 
Billerbeck et al identified a similar population with tissue-homing properties, but with 
Tc17 phenotype(Billerbeck et al. 2010).  More recently, CD161hi IL-18Rα+ CD8+ T 
cells were shown to be Vα7.2+ MAIT cells (mucosal associated invariant T 
cells)(Dusseaux et al. 2011). 
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In contrast, CD161-expressing CD4+ T cells have been less well characterized. 
Takahashi and colleagues showed that this population has a pro-inflammatory 
profile(Takahashi, Dejbakhsh-Jones, & Strober 2006). CD4+ T cells with 
intermediate expression of CD161 were also found with migratory capability across 
the endothelial monolayer (Poggi et al. 1997); nevertheless, this ability could be 
revoked by blocking CD161 using monoclonal antibodies(Bezouska et al. 
1994).Moreover, the naïve populations of CD4+CD161+ T cells, identified in umbilical 
cord blood, were shown to be the origin of IL-17-producing T cells(Cosmi et al. 
2008).These data suggest that CD161-expressing T cells are likely to represent a 
mixture of different T cell subsets, some of which may have stem cell-like memory 
properties. 
 
1.3.3 Regulatory T cells 
 
Maintaining immune tolerance to self antigens is crucial for the immune system to 
prevent autoimmunity. A variety of cells are involved in this process, including 
naturally occurring regulatory T cells (Tregs)(Albert et al. 2005;Cohen et al. 
2002;Hoffmann et al. 2002;Sakaguchi 2005),IFNγ/IL-10-secreting T regulatory type 
1 (Tr1)(Groux et al. 1997;Levings et al. 2001a), transforming growth factor-β-
secreting Th3 regulatory cells(Weiner 2001), natural killer T cells (NKT)(Seino et al. 
2001), and double negative cells (CD4-CD8-)(Zhang et al. 2000).Of these, naturally 
occurring regulatory T cells have been the principal focus of transplantation 
tolerance studies.  
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1.3.3.1 Naturally occurring regulatory T cells 
Although studies have suggested that naturally occurring regulatory T cells are 
generated as a distinct population in the thymus, CD4+CD25hiFoxp3+ Tregs that are 
identical to the thymus-derived population, can also be generated after antigen-
induced proliferation of CD4+ T cells in peripheral tissues in both mice and 
humans(Apostolou and von 2004;Cobbold et al. 2004;Vukmanovic-Stejic et al. 
2008). CD4+CD25hiFoxp3+ Tregs constitute 5-10% of total CD4+ T cells and play a 
pivotal role in immune tolerance by inhibiting auto-reactive T cell 
populations(Sakaguchi et al. 2001;Takahashi et al. 1998).  As such they are critical 
in the maintenance of normal immune homeostasis(Dudda et al. 2008).  In addition 
to their ability to suppress autoimmune reactivity, they can suppress reactions 
directed against non-self antigens(Sakaguchi 2005). Naturally, Tregs are anergic 
when stimulated in vitro. However, co-stimulation with anti-CD28 and high 
concentrations of IL-2 has been shown to break this hypo-responsiveness.  
By contrast, in vivo studies have shown the ability of these cells to accumulate and 
proliferate at the site of inflammation upon second antigen recall(Vukmanovic-Stejic 
et al. 2008). 
 
1.3.3.2 Characterization of naturally occurring regulatory T cells 
Regulatory T cells can be identified phenotypically by the expression of CD4 and the 
IL-2 receptor α chain, CD25(Sakaguchi et al. 1995). In addition, they are 
characterised by negative or low expression of CD127, the IL-7 receptor α chain(Liu 
et al. 2006). More recently, the forkhead/winged helix transcription factor protein 
(FoxP3), which is constitutively expressed in Tregs and involved in their 
development and suppressive functions, has been employed as an intracellular  
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marker for Tregs(Fontenot et al. 2003;Hori et al. 2003).  Mutation or disruption in the 
FoxP3 gene leads to a fatal multi-organ autoimmune disease in both human and 
mice, namely immunodysregulation polyendocrinopathy enteropathy X-linked 
syndrome (IPEX) and the scurfy mouse phenotype, respectively(Bennett et al. 
2001;Brunkow et al. 2001), demonstrating the critical role of this transcription factor 
in Treg function.  
 
T cells are divided into naïve and memory according to the expression of different 
isoforms of CD45. Whereas naïve T cells express CD45RA (Valmori et al. 2005) the 
memory counterpart possess the CD45RO isoform. This classification of T cell 
subsets has been shown to correlate with Tregs functions and propagation 
(Vukmanovic-Stejic et al. 2006;Hoffmann et al. 2006).More detailed characterization 
of Treg cell subpopulations, naïve and memory, based on the deferential expression 
of CD45RA and FoxP3 has also been reported (Miyara et al. 2009). Further 
characterization was also introduced on the basis of the expression of homing 
receptors, namely CD62L and CCR7 (Sallusto et al. 1999; Tosello et al. 2008). In 
transplant setting, regulatory T cells expressing CD62L have exhibited higher 
suppressive potential and were able to control GvHD than their CD62L- counterparts 
(Ermann et al. 2005;Taylor et al. 2004). 
 
Other markers that are commonly used for Treg identification, include cytotoxic T 
lymphocytes antigen-4 (CTLA-4), glucocorticoid induced tumour necrosis factor 
receptor (GITR) and more recently tumour necrosis factor receptor 2 (TNFR2)(Chen 
et al. 2010;Shimizu et al. 2002;Takahashi et al. 2000). Although FoxP3 and CTLA-4 
are among the most reliable markers for the identification of regulatory T cells, they 
cannot be employed for the selection of functional Tregs due to their intracellular 
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expression. To overcome this problem, several groups have focussed on finding a 
reliable surface marker. Recently, CD39 (the ectoenzyme which degrades ATP to 
AMP) and CD49d ( the α-chain of the integrin VLA-4 (α4β1)), have been used along 
with CD4+, CD25hi and CD127low as markers to facilitate the isolation of functionally 
active untouched Foxp3+ Tregs(Borsellino et al. 2007;Kleinewietfeld et al. 
2009;Mandapathil et al. 2009). Other markers include the tumour-necrosis factor 
receptor family member CD27(Ruprecht et al. 2005)and HLA-DR(Baecher-Allan et 
al. 2006), although both are limited in their selectivity. 
 
1.3.3.3 Regulatory T cells-mechanisms of action 
The exact mechanisms by which CD4+CD25+Foxp3+ regulatory T cells exert their 
anti-inflammatory and immunoregulatory functions are not fully understood. To date, 
efforts to identify these mechanisms have cast some light on the topic but progress 
has been hampered by conflicting data. The majority of in vitro studies have shown 
that Tregs require cell contact to exert their suppressive effect(Nakamura et al. 
2001). However, a key role of immunoregulatory cytokines such asIL-10, TGF-β and 
IL-4 in T cell-mediated suppressive activities has also been demonstrated in both in 
vitro and in-vivo neutralization studies(Asseman et al. 1999;Powrie et al. 
1996;Seddon and Mason 1999). 
 
In addition to these two main mechanisms, Edinger et al have shown perforin 
dependency of these cells in the control of allo-reactions in GvHD(Edinger et al. 
2003).  In a recent study by Cai and colleagues, granzyme-B was reported to be an 
important player in the suppressive action of Tregs against anti-tumour effector T 
cells (mediating GVL), but not important in suppressing allo-reactive effector T cells 
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in GvHD; this suggests that the manipulation of granzyme-B could allow separation 
of the two phenomena(Cai et al. 2010;Cao et al. 2007). 
 
1.3.3.4 Targets of regulatory T cells 
A variety of effector cells, most notably those of the adaptive immune system such 
as CD4+and CD8+T cells, as well as other immune subsets such as NK and B cells 
have been shown to be the main targets for Treg suppressive activity(Iikuni et al. 
2009;Kim et al. 2006;Levings et al. 2001b;Pandiyan et al. 2007;Piccirillo and 
Shevach 2004;Simon et al. 2007). Interestingly, it has been shown that once 
activated, T regulatory suppressor function are non-specific(Thornton and Shevach 
2000) and  therefore, it may also be possible for these cells to control innate 
immunity. Conversely, recent work has shown that there may in fact be counter-
regulation of regulatory T cells by innate immune mechanisms(Kim et al. 2009). 
 
The manipulation of regulatory T cells in the allogeneic stem cell transplant setting 
has the potential to achieve two opposing, although not necessarily mutually 
exclusive effects: their depletion to enhance anti-tumour immunity (Heier et al. 
2008;Imai et al. 2007;Kline et al. 2008) or harnessing their regulatory capacity to 
achieve protection from autoimmunity, graft rejection and critically, GvHD. The 
segregation and optimisation of these two effects is at the forefront of current 
allogeneic stem cell transplant research. 
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1.3.4 Plasticity between T cell subsets 
Different Th cell subsets have been historically considered as terminally 
differentiated, recognised mainly by their ability to produce specific cytokines and 
express a unique transcriptional profile. However, recent compelling data suggest 
more flexibility in the phenotype of differentiated T cell subsets, hence challenging 
this paradigm. This flexibility has been noted to include the shared production of 
cytokines that were previously assigned for a specific phenotype such as IL-10 
(considered to be of Th2 origin) or IL-21(Saraiva and O'Garra 2010;Suto et al. 
2008). Additionally, lack of fundamental factors for differentiation could drive this 
plasticity. For instance, Th17 cells, in the absence of TGF-β which is required for 
their development, can acquire a Th1 phenotype(Hirota et al. 2011;Lee et al. 2009b).  
Likewise, regulatory T cells under certain circumstances upregulate the Th1 master 
regulator T-bet and produce IFNγ(Dominguez-Villar et al. 2011;Oldenhove et al. 
2009). Furthermore, in addition to their own transcription factors and cytokines, T 
cell subsets may express transcription factors and/or produce cytokines from T cells 
of a different phenotype. For example, although regulatory T cells were defined by 
the expression of Foxp3, under certain conditions they were shown to express the 
Th17 master transcriptional factor, RORγt, and produce IL-17(Voo et al. 2009). 
Similarly, Foxp3+ regulatory T cells were shown to have the ability to express the 
master regulators of Th1 (T-bet) and Th2 (GATA3)(Koch et al. 2009;Wang et al. 
2011;Wohlfert et al. 2011). Finally, a subset of Th17 cells with high pathogenic 
potential in murine models was also found to co-express other transcription factors 
such as T-bet(Ghoreschi et al. 2010;Yeh et al. 2011). 
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Figure ‎1.3: Plasticity between helper T cell subsets. The Figure shows the potential to 
acquire different phenotype through mutual expression of the master regulators. Adopted 
from Nakayamada et al, 2012. 
 
 
 
 
 
 Abdullah S. Alsuliman  PhD Thesis, 2013 
 
38 
1.4 CD4+ T cell subsets and GvHD/GvL 
1.4.1 Animal studies of Th17, CD4+CD161+T cells, Tregs and GvHD 
1.4.1.1 Helper T cell type 17 and CD161+CD4+ T cells 
Historically, acute GvHD was thought to be mediated exclusively by IFNγ-producing 
T cells (Th1)(Allen et al. 1993). Administration of T helper 1 inhibitors was found to 
protect mice from GvHD (Lu et al. 2001) and selective deletion of the Th1 
transcription factor T-bet prevented GvHD while allowing GvL. However, other 
studies in murine models reported that IFNγ-deficient mice developed much more 
severe GvHD compared to the wild-type(Murphy et al. 1998;Yang et al. 1998). 
These conflicting findings shifted the focus of GvHD researchers to study the role of 
other T cell subsets in the pathogenesis of GvHD.  
 
Recently, the role of Th17 cells in GvHD pathogenesis has been addressed. Carlson 
et al demonstrated that infusing IL-17-producing T cells generated in vitro into 
lethally-irradiated mice was sufficient to induce acute GvHD in skin and lung. 
Interestingly, neutralizing IL-17 by a monoclonal antibody abrogated this 
effect(Carlson et al. 2009). In another study, although no difference was observed in 
GvHD related deaths in recipients of wild type (WT) and IL-17 knock-out (KO) T 
cells, transfer of IL-17 KO CD4+ T cells into allogeneic recipients delayed the onset 
of GvHD when compared to WT CD4+ T cells(Kappel et al. 2009). Furthermore, 
suppression of IL-17 production from G-CSF-treated CD4+ T cells by SOCS3 
induction was shown to ameliorate acute GvHD(Joo et al. 2012).  On the other hand, 
IL-17-deficient donor CD4+T cells accelerated GvHD in the recipients through 
enhancing Th1 differentiation(Yi et al. 2008), suggesting an immunomodulatory 
function of Th17 cells on Th1 cells. 
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In a different approach to assess the importance of Th17 cells in GvHD 
pathogenesis, two different groups have evaluated the consequence of interfering 
with the Th17 specific transcription factor RORγt. Yu and colleagues have shown 
that deleting both RORγt and T-bet, but not RORγt alone, ameliorates GvHD while 
sparing its beneficial counterpart, GvL(Yu et al. 2011). In contrast, a more recent 
report determined that deleting both isoforms of RORc (RORt and RORγt) in CD4 
and CD8 was sufficient to mitigate the severity of GvHD in allo-recipients(Fulton et 
al. 2012). 
 
Other reports have also supported the involvement of Th17 cells in GvHD mouse 
models. For instance, several studies have shown that blockade of cytokines 
involved in Th17 differentiation such as IL-6, IL-21 and IL-23 can reduce the 
incidence of GvHD(Bucher et al. 2009;Chen et al. 2009b;Das et al. 2010;Tawara et 
al. 2011). Additionally, the mechanism of action halofuginone, an inhibitor of skin 
collagen deposition in GvHD, was shown to be mediated through inhibition of Th17 
differentiation and function(Cheng et al. 2012). 
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1.4.1.2 Regulatory T cells 
Several studies using animal models have demonstrated the prominent role of 
regulatory T cells in the prevention of GvHD and more interestingly in the separation 
of GvHD from favourable GvL. Depletion of CD4+CD25+T cells has been shown to 
accelerate and exacerbate GvHD whereas the adoptive transfer of these cells can 
rescue mice from such harmful effects(Taylor et al. 2002b). Furthermore, 
CD4+CD25+T cells can prevent GvHD-related damage of the thymus and peripheral 
lymphoid tissues, which in turn facilitates the development and expansion of an 
enhanced T cell repertoire, resulting in improved reconstitution of functional immune 
responses following AHSCT(Nguyen et al. 2008).  Regulatory T cells can also 
prevent the production of pro-inflammatory cytokines, such as IFN, IL-17, IL-1 and 
G-CSF that are mediators of chronic GvHD(Chen et al. 2007). 
 
Different sub-populations of Tregs have different regulatory potency. 
CD4+CD25+CD62L+ were shown to be more effective at preventing GvHD, whereas 
their counterpart CD62L- fraction did not demonstrate the same anti-GvHD capacity.  
This differential effect may be related to the ability of the CD62L+ Treg sub-
population to home to secondary lymphoid organs more efficiently and therefore 
more effectively exert their protective function against acute GvHD(Ermann et al. 
2005;Taylor et al. 2004).It is possible to break the anergic status of Tregs in vitro 
using TCR ligation, co-simulation and cytokines.  Ex-vivo expanded Tregs are even 
more suppressive than their fresh counterparts(Jones, Murphy, & Korngold 
2003;Taylor, Lees, & Blazar 2002b). 
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Recently, Beyersdorf et al showed that Tregs isolated from animals that were pre-
treated with super-agonistic anti-CD28 displayed enhanced suppressive activity and, 
following adoptive transfer, protected recipients from acute GvHD without abrogating 
the beneficial GVL effect of CD28 pre-activated effector T cells(Beyersdorf et al. 
2009).  The suppressive ability of regulatory T cells has been shown by some 
groups to be antigen-specific, as third party recipients are not protected from 
GvHD(Joffre et al. 2004; Trenado et al. 2003).  Conversely, others have shown  that 
once activated, regulatory T cells act in a non-specific manner(Thornton & Shevach 
2000).  CD4+CD25+T cells can also suppress CD8-mediated GvHD across minor 
histocompatibility barriers (Jones, Murphy, & Korngold 2003) and were shown to be 
suppressive in xenogenic antigen-mediated GvHD(Cao et al. 2009b). 
 
The paucity of regulatory T cells in the peripheral blood and their unknown specificity 
has been a challenge to employing these cells in transplantation tolerance. 
However, several groups have successfully expanded polyclonal, as well as antigen-
specific regulatory T cells using several different expansion strategies. Taylor and 
colleagues have evaluated different methods for polyclonal expansion, including 
immobilized anti-CD3 with low dose IL-2 in the presence of TGF- (yielding the 
highest frequency and most suppressive population), and soluble anti-CD3 with APC 
or high concentration IL-2(Taylor, Lees, & Blazar 2002b). Stimulating Tregs with 
anti-CD3/CD28 microbeads with IL-2 (Taylor et al. 2004;Trenado et al. 2006) or with 
IL-15(Karakhanova et al. 2006)has also been shown to result in successful 
expansion of polyclonal regulatory T cells.  
 
An alternative approach is the use of lentivirus to ectopically express Foxp3 in 
CD4+CD25- T cells. These engineered regulatory T cells were shown to be  
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phenotypically and functionally similar to natural T regulatory cells and able to 
suppress GvHD while preserving GVL in a murine EL4/DsRed leukaemia model(Cao 
et al. 2009a). 
 
Although polyclonal regulatory T cells have been shown to possess sustainable 
phenotypic and functional characteristics of regulatory T cells(Godfrey et al. 2004) 
and have the ability to delay or protect from GvHD, their effect on beneficial immune 
responses is not fully understood. Therefore, the idea of expanding regulatory T 
cells with a particular specificity, so-called recipient allo-antigen specific T cells, has 
emerged in transplantation models. The advantage of using antigen-specific over 
polyclonal regulatory T cells has been proven in different settings such as diabetes 
(Tang et al. 2004) and solid organ transplantation. Trenado et al have shown that 
recipient-specific regulatory T cells, generated by expanding donor regulatory T cells 
with recipient APCs, were able to prevent GvHD while preserving GVL; with some 
variation according to tumour cells used(Trenado et al. 2003).  The specificity of this 
protection was further assessed using a graft rejection model whereby mice were 
transplanted with syngeneic bone marrow (BM) and two different allogeneic BMs 
along with syngeneic splenocytes (stimulator), in the presence of allo-activated 
CD4+CD25+ Tregs. Only BM, from which APCs were used to activate the Tregs, was 
protected from rejection, whilst the third party BM was not(Joffre et al. 2004).  As 
would be expected, expanded antigen-specific regulatory T cells were even more 
suppressive than polyclonal ones. As is the case with adoptive immunity, specificity 
is preferable. Many protocols have been and continue to be developed aiming to 
generate antigen-specific regulatory T cells.  However, further research is needed to 
achieve the required specificity to enable these powerful cells to be translated to 
human applications.  
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1.4.2 Clinical evaluation of Th17 and regulatory T cells in GvHD 
1.4.2.1 Helper T cells type 17 and CD4+CD161+ T cells 
 
Th17 involvement in the pathogenesis of acute GvHD in humans has also been 
investigated. In a report measuring the frequencies of Th17 cells using ELISPOT 
and IL-17 plasma levels by ELISA, patients with acute GvHD were shown to have 
higher Th17 frequencies and increased IL-17 plasma levels when compared to 
healthy controls and patients with no sign of aGvHD(Dander et al. 2009). Likewise, 
Zhao and colleagues showed that patients who received more Th17 cells in the graft 
were more likely to develop acute GvHD. The authors demonstrated that the 
frequency of IL-17+ T cells was higher at GvHD onset and response to treatment for 
GvHD was associated with a reduction in Th17 cells. In keeping with murine studies, 
exposure to G-CSF was found to decrease the number of Th17 cells(Zhao et al. 
2011). Similarly, in a recent report by Bossard et al, the absolute number of Th17 
cells in the intestinal mucosa was higher in patients with aGvHD compared to 
healthy controls and patients with no GvHD. Th17 infiltration was assessed indirectly 
using immunohistochemistry staining forCD161+ CCR6+ and the transcription factor 
RORγt. Moreover, they found that the intestinal mucosa of patients with aGvHD had 
more plasmacytoid dendritic cells, which have been shown to play a role in Th17 
differentiation(Bossard et al. 2012). 
 
In contrast, findings from two other groups do not support a role for Th17 cells in 
acute GvHD pathogenesis. One group showed that T cells isolated from the skin of 
patients with aGvHD produce more IFNγ, but not IL-17 or IL-22. In addition, they 
found no significant difference in the frequencies of Th17 cells in the peripheral  
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blood of patients with or without aGvHD patients(Broady et al. 2010). Using 
immunohistochemistry, Ratajczak et al found no difference in Th17 infiltration of 
aGvHD targets such as skin and gastrointestinal tract in aGvHD and no GvHD 
patients(Ratajczak et al. 2010). 
 
Analysis of single nucleotide polymorphism (SNP) is another approach used to 
evaluate the role of Th17 in aGvHD pathogenesis. A Japanese group showed that 
recipients with 197A genotype at rs2275913 in the promoter region of the IL-17A 
gene were more likely to develop aGvHD(Espinoza et al. 2011b). Furthermore, in a 
separate report, the same group demonstrated that T cells from healthy controls with 
the 197A allele produced more IL-17 than T cells from donors with the 197G allele. 
They concluded that a graft from a donor with the 197A allele is more likely to 
contribute to the risk of aGvHD(Espinoza et al. 2011a). Similarly, a comprehensive 
genetic analysis of IL-23/Th17 variants in patients undergoing T-depleted AHSCT 
has shown that TC and CC genotype of the patients at rs8193036 in the IL-17A 
gene were associated with higher risk of aGvHD(Carvalho et al. 2010). 
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1.4.2.2 Regulatory T cells 
The translation from murine Treg models into the human clinical setting remains in 
its infancy.  Early work in the field yielded conflicting data, partly because of 
difficulties in the use of markers to accurately identify true regulatory T cells and 
discriminate them from activated T cell effectors.  Indeed some early studies 
reported a correlation between GvHD occurrence and high Treg frequency, defined 
as CD4+CD25+T cells, both in the graft (Stanzani et al. 2004)and in the 
recipient(Clark et al. 2004).  Others failed to show a correlation between 
CD4+CD25+content and outcome in the setting of donor lymphocyte infusion (DLI); 
although the addition of a further discriminatory marker defining Treg as CD25hi 
CD45RBlow, did show a relationship between higher DLI CD4+CD25hiCD45RBlow cells 
and lower severity of GvHD(Mutis et al. 2005).  However, these early works used 
CD25+ as the only marker for identifying Treg which is also expressed on activated T 
cells, rendering these data difficult to interpret due to the probable overlap between 
regulatory and activated T cell populations in these studies.  
 
The use of Foxp3 as a marker for the identification of regulatory T cells served to aid 
progress in the field and human observational studies demonstrated that decreased 
Foxp3 expression, measured by flow cytometry and PCR techniques, correlates with 
a heightened incidence of both acute and chronic GvHD post allogeneic stem cell 
transplant(Miura et al. 2004;Zorn et al. 2005).  Rezvani et al have shown an 
association between the Treg content of the graft and GvHD(Rezvani et al. 2006). 
The number of transfused Treg within the graft has been shown to also affect overall 
survival post-transplant(Vela-Ojeda et al. 2010). Furthermore, high percentage and  
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absolute number of Foxp3+CD4+T cells in both donor graft and the recipient blood 
early after AHSCT was found to correlate with a low incidence of GvHD(Rezvani et 
al. 2006).However, when CD25+T cell content, which had previously been employed 
as a marker for regulatory T cells, was analysed independently, there was a direct 
correlation between CD4+CD25+ and increased incidence of GvHD -  further 
confirming the inadequacy of CD25+ as a stand-alone marker for Tregs.  Even 
following the selective depletion of CD25+T cells in the graft using anti-CD25 
immunotoxin, the CD4+Foxp3+ regulatory T cell compartment reconstituted 
promptly(Mielke et al. 2007).These data were further supported by a recent study, 
reporting that the balance between Tregs and T-effector cells is important in 
determining outcome from GvHD(Matthews et al. 2009).In contrast, others failed to 
show a correlation between Foxp3 expressing Treg and the incidence of 
GvHD(Meignin et al. 2005).The discrepancy in these results is probably related to 
the heterogeneity of the patient groups and the treatment regimen in the different 
studies. 
 
Recent published data of the comparative examination of pathological specimen 
have shown an association between the Treg frequencies in the affected organs and 
severity of GvHD. Rieger et al demonstrated a post-transplant shift in the T cell 
repertoire during GvHD with reduced numbers of peripheral blood CD4+CD25hi 
regulatory T cells, accompanied by a reduction in gastrointestinal (GI) mucosal 
Foxp3 expression(Rieger et al. 2006).   
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Others have reported higher number of Tregs in the skin of patients with aGvHD that 
responded to therapy compared to those with resistant aGvHD, illustrating their 
important role, even in established disease(Fondi et al. 2009).  These data have led 
to a proposal to consider Treg frequencies as diagnostic and prognostic biomarkers 
for aGvHD(Magenau et al. 2010). 
 
The potential suppressive effect of Treg on the useful anti-tumour responses in 
humans remains largely unknown. Whereas in some murine studies, the protection 
from aGvHD has been reported without the loss of anti-tumour immune responses, 
clinical data reported in the literature are conflicting.  Nadal et al examined a cohort 
of patients transplanted for chronic myeloid leukaemia (CML) and found that, 
although an increment in Tregs may have an advantageous effect on graft survival in 
the early post-transplant phase, this was associated with a loss of GvL effect and a 
consequent increase in relapse rate.  Furthermore, their data failed to support a role 
for Tregs against aGvHD(Nadal et al. 2007). The weight of published data however 
favours regulatory T cells as potentially useful therapy in GVHD without reducing 
GvL. 
 
 
 
 
 
 
 Abdullah S. Alsuliman  PhD Thesis, 2013 
 
48 
1.4.3 Treg and Th17 imbalance in GvHD 
The disturbance in the balance between regulatory T cells and Th17 cells have been 
proposed to play a role in autoimmune diseases as well as AIDS 
pathogenesis(Alunno et al. 2012;Kanwar et al. 2010;Niu et al. 2012;Prendergast et 
al. 2010). However, the importance of Treg and Th17 ratio in the stem cell 
transplantation setting is poorly understood. In mice, G-CSF treatment has been 
shown to attenuate acute GvHD. In this study, although the percentage of CD4+ 
Foxp3+ Treg did not change significantly, exposure to G-CSF reduced the number of 
Th17 cells, resulting in a skewing in the Treg/Th17 ratio in favour of protection 
against aGvHD(Joo et al. 2012).   In addition, monoclonal antibodies used to 
inactivate IL-6 have been shown to shift the balance between Treg and Th17 
cells(Chen et al. 2009b;Noguchi et al. 2011). Likewise, neutralizing IL-21, another 
Th17 differentiation-related cytokine, has been shown to control GvHD through 
manipulating the Treg/Th17 ratio(Bucher et al. 2009). 
 
In human studies, the observed contribution of IL-17-producing CD4+T cells to the 
onset of acute GvHD has also been associated with a drop in the frequencies of 
CD4+CD25+Foxp3+ T cells(Dander et al. 2009). Additionally, despite demonstrating 
the indispensable role of Th17 in aGvHD, Ratajczak and colleagues concluded that 
the Th17/Treg ratio is a more useful predictive marker for skin and gastrointestinal 
GvHD(Ratajczak et al. 2010). 
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1.5 Immunosuppressive drugs used for prophylaxis and 
treatment of GvHD and their impact on Th17 and Regulatory T 
cells. 
Various strategies are employed to prevent or attenuate GvHD through dampening 
pathogenic alloresponses and suppression of effector T cells subsets e.g. Th17 
cells.  
 
1.5.1 Corticosteroids 
The use of corticosteroids as a first-line intervention for acute GvHD is routine in the 
management of this disease. Irrespective of the variable outcome of this treatment 
modality, it is favourably used due to its anti-inflammatory as well as cytotoxic 
activity. However, the effect of steroids on Th17 and regulatory T cells has not been 
well addressed. The effect of steroids treatment on IL-17 production is 
controversial(Liu et al. 2009;McKinley et al. 2008;Prado et al. 2011a;Yang et al. 
2009).In addition, previous data have suggested that Foxp3+ Treg cells are resistant 
to the effect of steroids; however the suppressive ability of Tregs was impaired in 
this study(Karagiannidis et al. 2004;Prado et al. 2011b). 
 
1.5.2 Immunosuppressive drugs used for GvHD prophylaxis 
1.5.2.1 Anti-thymocyte globulin (ATG) 
Anti-thymocyte globulin has been used for the prophylaxis and treatment of GvHD 
as well as wider clinical applications that harness its potent immunosuppressive 
action e.g. in the management of aplastic anaemia.  More recently it has been 
suggested that ATG may preferentially deplete conventional T cells, while sparing 
regulatory T cells(Feng et al. 2008). 
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However, work seeking to evaluate the notion that rabbit anti-thymocyte globulin 
(rATG) may provide protection from GvHD through the enhancement of regulatory T 
cells, has shown that although Foxp3 expression increases in human T cells 
exposed to rATG, the increase in Foxp3+ T cells is only transient.  Furthermore, 
Foxp3 positive T cells induced following exposure to rATG do not appear to have 
immunosuppressive capacity, even at the time of maximal Foxp3 expression(Broady 
et al. 2009). 
 
1.5.2.2 mTOR inhibitor (Rapamycin) 
Rapamycin, an mTOR inhibitor, has been shown to effectively induce Tregs both in 
vitro and in vivo(Battaglia et al. 2005;Thornton et al. 2004).Furthermore, rapamycin 
was found to prevent the differentiation of Th17 in vitro(Kopf et al. 2007).This agent 
has been used successfully in the prophylaxis and treatment of GvHD post 
AHSCT(Ghez et al. 2009). However, in contrast to other classical prophylactic 
agents such as cyclosporine and tacrolimus, rapamycin exerts a differential effect on 
regulatory and conventional effector T cell populations, leading to an increase in the 
Treg:T effector ratio(Coenen et al. 2007).  Recent data from the murine setting have 
shown that post allograft, rapamycin results in an increase in the frequencies of 
Tregs in GvHD target organs, such as the skin, although circulating numbers of 
Tregs are unaffected(Palmer et al. 2010).Similarly, a recent report by Shin and 
colleagues has shown that administering rapamycin and IL-2 together expanded 
Treg more efficiently and provided protection against aGvHD(Shin et al. 2011). 
These studies have not investigated the effect of rapamycin on the Th17 subset. 
Such pathological data in the human allograft setting is as yet unavailable, 
principally due to the difficulties in obtaining such samples from patients. 
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1.5.2.3 Calcineurin inhibitors (CNI) 
Calcineurin inhibitors are widely used in GvHD prophylaxis prior to AHSCT. By 
interfering with calcineurin activity, these agents inhibit IL-2 dependent T cell 
activation. However, their exact influence on the Th17 and Treg axis has not been 
well studied. Previous studies have generated conflicting data on the effect of 
calcineurin inhibitors on Tregs; on the one hand they support a role for low doses of 
calcineurin inhibitors in inducing regulatory T cells(Brandt et al. 2009;Wang et al. 
2009b) whereas other data suggest that they may reduce Tregs in favour of pro-
inflammatory T cell expansion(Lopez-Flores et al. 2011;Miroux et al. 2009;Miroux et 
al. 2012;Wang et al. 2006). Unexpectedly, although they interfere with IL-2, 
previously shown to prevent Th17 differentiation, CNI generally have a suppressive 
effects on IL-17 production(Cho et al. 2007;Chung et al. 2012;Fabrega et al. 
2009;Tsuda et al. 2012;Yago et al. 2012;Zhang et al. 2008). However, further 
studies are needed to understand the influence of CNI on the Treg/Th17 balance 
and their role in GvHD.   
 
1.5.3 Cytokine therapy 
IL-2 is an essential cytokine in the maintenance of the pool of Treg cells in vivo and 
is also critical to their function.  Furthermore, in the lymphopenic setting such as 
might be encountered immediately following allogeneic stem cell transplantation, IL-
2 may preferentially promote the expansion of the Treg compartment(Zhang et al. 
2005a).  IL-2 directly up-regulates Foxp3 gene expression through the 
phosphorylation of STAT proteins that subsequently translocate to the nucleus and 
bind to regulatory motifs in the Foxp3 gene(Wuest et al. 2008).Conversely, 
manipulation of STAT proteins by IL-2 was found to suppress  
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Th17 differentiation (Laurence et al. 2007) and the silencing of IL-2 gene expression 
was shown to reverse this effect(Quintana et al. 2012).Exogenous use of this 
cytokine had therefore been proposed as a potential immunomodulatory therapy to 
boost the number of Tregs post AHSCT.   
 
In support of this, Rouse et al, have shown the reciprocal effect of IL-2 on Treg and 
Th17 cells and their impact on controlling experimental autoimmune 
encephalomyelitis(Rouse et al. 2012).For Treg to preferentially expand in vivo, 
adequate numbers of Tregs is necessary at baseline (Thornton, Donovan, Piccirillo, 
& Shevach 2004).  Recently Zorn et al reported the feasibility of a clinical study of 
low-dose IL-2 combined with infusions of donor CD4+ lymphocytes to expand Tregs 
in vivo(Zorn et al. 2009). Concerns remain that this approach may diminish the GVL 
action of effector T cells. Therefore, carefully monitored, prospective clinical trials 
are required to explore the efficacy of this strategy further. 
 
1.5.4 Extracorporeal photopheresis (ECP) 
ECP is used for the treatment of chronic graft versus host disease, although the 
exact mechanism for the efficacy of this therapy remains unclear.  Leukapheresed 
peripheral blood mononuclear cells are treated with UVA radiation in the presence of 
a DNA alkylating agent that induces apoptosis.  It is proposed that upon 
phagocytosis by antigen presenting cells, tolerogenic signals are induced resulting in 
reduced graft versus host disease.  The precise nature of these tolerogenic signals 
and the cell phenotypes involved have been an area of active investigation. A 
number of groups have shown that induction or differentiation of regulatory T cells is  
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an important component of this tolerogenic response(Lamioni et al. 2005;Maeda et 
al. 2005). In addition to an increase in Treg frequencies, each successive cycle of 
treatment with ECP leads to an increase in the suppressive capacity of these 
cells(Rao et al. 2009;Schmitt et al. 2009).  Di Biaso et al recently demonstrated that 
only patients responding to ECP have a rise in their fraction of circulating Tregs 
whereas patients who fail to respond to the therapy have no such rise in Treg 
numbers.  In addition they identified a concurrent decrease in the CD4+ T cells 
producing interleukin-17 in patients responding to ECP(Di, I et al. 2009). 
 
Recently, Pappa and colleagues have shown a similar reciprocal association 
between Treg and Th17 cells in systemic sclerosis patients treated with ECP(Papp 
et al. 2012). These studies further support the importance of the recently described 
Th17 axis in the pathology of GvHD and its frequent reciprocal relationship with the 
regulatory T cell axis(Carvalho et al. 2010;Dander et al. 2009). 
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1.6 Regulatory T cells as cellular therapy for acute GvHD 
The most established model of cellular therapy is in the setting of DLI. DLI is 
employed to augment the graft versus leukaemia response post AHSCT, either to 
treat relapsed disease or pre-emptively to prevent relapse, particularly in the context 
of reduced intensity conditioning transplant regimens. Increasingly other cell-based 
therapies are being used in the clinic – mesenchymal stem cells have been 
employed as successful GvHD therapy(Dazzi and Marelli-Berg 2008) and illustrate 
the feasibility of expanding the necessary GMP (good manufacturing practices) 
standards to a range of cellular products including regulatory T cells for therapeutic 
adoptive transfer.  
 
Tackling the source of regulatory T cells, given their low frequencies in peripheral 
blood, has been a major block in their development as a viable cellular therapy.  
Several methodologies have been under development to overcome this obstacle, 
either through polyclonal or antigen-specific expansion of these cells.  The in vitro 
conversion of conventional T cells (CD4+CD25-) into polyclonal cells with a Treg 
phenotype has been achieved using specific cytokines, such as retinoic acid(Wang 
et al. 2009a) and/or TGF-B(Chen et al. 2003;Park et al. 2004) in addition to IL-2, 
which plays a critical role in the expansion of Tregs. The use of agonistic antibodies 
against stimulatory and co-stimulatory molecules, mainly CD3 and CD28, has also 
been shown to be effective in expanding these cells(Godfrey et al. 2004;Hoffmann et 
al. 2004;Taylor et al. 2002a;Taylor, Lees, & Blazar 2002b).  Anti-CD28 super-agonist 
were shown to preferentially expand the Treg compartment(Kitazawa et al. 2009), 
however translation of this approach in a recent clinical trial failed to yield significant 
preferential Treg generation(Suntharalingam et al. 2006).  Several studies have also 
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focused on the expansion of antigen-specific regulatory T cells, employing cellular 
mediators to promote Treg expansion.  
 
Yamazaki and colleagues have directly expanded Tregs using dendritic cell 
stimulation(Yamazaki et al. 2006). Allogeneic B cells(Chen et al. 2009a) or CD40-
activated B cells(Tu et al. 2008) have also been suggested as stimulators to 
generate and expand alloantigen-specific Tregs. CD40-activated B cells were shown 
to be more efficient at generating Tregs with  more suppressive activity, compared to 
immature dendritic cells(Zheng et al. 2010).  An alternative methodology has been 
ex-vivo selection of CD4+CD25+ natural regulatory T cells and their in vitro 
expansion.  Regulatory T cells are selected according to CD4+CD25+ phenotype for 
either direct adoptive transfer or in vitro expansion; this raises the issue of activated 
conventional T cell contamination of the collected product, which might in turn skew 
the benefits expected.  It is therefore important to further characterize these cells 
phenotypically to achieve accurate selection and expansion of a pure regulatory T 
cell product. 
 
The technology is now ripe for transfer into the human clinical setting, in carefully 
conducted and closely monitored trials – only then will it become possible to glean 
answers to questions on optimal dose, timing, compatibility with other 
immunosuppressive drugs and critically, safety in terms of relapse of underlying 
disease and susceptibility to infection. 
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1.7 Adoptive Treg Transfer – Clinical Trials 
The first human study of adoptive transfer of ex vivo expanded CD4+CD25+CD127- T 
regulatory cells in the treatment of GvHD was reported in October 2009 in two 
patients, using cells expanded from buffy coats taken from family 
members(Trzonkowski et al. 2009).  The first patient, who was being treated for 
chronic GvHD, achieved significant alleviation of symptoms and reduction of 
pharmacologic immunosuppression.  However, the second patient, who was being 
treated for grade IV acute GvHD, experienced only transient improvement.  A 
number of phase I clinical studies, currently ongoing, have employed both freshly 
isolated donor Tregs administered alongside DLI, and Tregs expanded from 
umbilical cord blood administered in the double cord blood transplant setting(Claudio 
Brunstein 2009;Riley et al. 2009).   Recently, Di Ianni and colleagues conducted a 
phase I/II clinical trial involving twenty-two patients with haematological 
malignancies, receiving a haploidentical AHSCT (Mauro Di Ianni and Mauro Di 
Ianni* 2009).  Patients received freshly isolated CD4+CD25hi regulatory T cells after 
transplant conditioning therapy followed by infusion of mobilized CD34+ stem cells 
and conventional T cells from their haploidentical donor.  The infused Tregs:Tcons 
ratio was established at 1:1.5 and no post-transplant prophylaxis against GvHD was 
used.  Strikingly, only 2 of 26 evaluable patients developed GvHD.  The authors 
concluded that in the setting of haploidentical transplantation, the success of which 
has been thwarted by infection-related deaths due to aggressive 
immunosuppression needed to prevent GvHD, infusion of freshly purified Tregs may 
allow safe administration of high doses of T cells, providing protection from GvHD 
and facilitating robust immune reconstitution.   
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Hypothesis and Aims 
I hypothesize that the balance of regulatory T cells and IL-17-producing CD4+ T cells 
may play a significant role in the pathogenesis of aGvHD.  
 
The aims of this thesis are two-fold: I will define stem cell-like memory CD4+ T cells 
with drug-effluxing capacity and will evaluate if they play a role in long-term memory 
against pathogens. I will examine if stem-like memory CD161+CD4+ T cells have a 
Th17 cytokine profile and will evaluate if they resist the lymphocytotoxic effect of 
corticosteroids, a substrate of the ABCB1 transporter complex, through their MDR 
pump, thereby contributing to steroid-refractory GvHD. 
The specific aims of this thesis are: 
1. To evaluate the existence of stem cell-like memory T cells with drug-
effluxing ability in the peripheral blood of healthy controls and patients 
with AML. 
2. To examine the functional phenotype of drug effluxing CD4+ and CD8+ T 
cells including their Th1 and Th17 profile. 
3. To examine mechanisms of steroid-refractory GvHD by assessing the in 
vitro and in vivo resistance of T cell subsets (Th1, Th17 and Tregs) to 
corticosteroids as well as calcineurin and mTOR inhibitors. 
4. To evaluate the impact of donor T cell subsets (Th1, Th2, Th17 and 
Tregs) infused with the graft on risk of GvHD. 
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CHAPTER 2. MATERIAL AND METHODS 
 
2.1 Patients and Samples 
Informed consent for the use of patient material was obtained from all patients at 
Imperial NHS Trust, Hammersmith Hospital. The study was approved by both the 
National Research Ethics Committee (NREC) and the local ethics review board. 
Peripheral blood mononuclear cells (PBMC) were collected from patients undergoing 
AHSCT prospectively before and at regular time points following AHSCT: days 30, 
60, 90, 120 and 180 days post-transplant.                
 
Informed consent for the use of archived patient material was obtained from all 
patients at initial presentation to Imperial NHS Trust, Hammersmith Hospital. 
 
2.2 Sample processing  
2.2.1 Isolation of Peripheral Blood Mononuclear Cell (PBMC) 
A maximum of 20-30ml of whole blood was collected from patients and healthy 
controls. Peripheral blood mononuclear cells (PBMCs) were isolated using density 
gradient separation technique (Lymphoprep). Briefly, 15 ml heparinised whole blood 
was diluted 1:1 with RPMI 1640 media (GIBCO / Invitrogen) in a 50ml falcon tube 
and 10ml of lymphoprep (Axis Shield, UK) was gently layered under the diluted 
blood.  
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After centrifugation at 1800 rpm for 30 min, the interface layer between plasma and 
lymphoprep, which contains mononuclear cells, was collected and re-suspended in 
fresh RPMI 1640. Cells were washed twice with RPMI 1640 media at 1200 rpm for 
10 min. PBMC were resuspended in 10% fetal calf serum (FCS)/ RPMI, counted 
using Trypan Blue (TB) for cell viability assessment. 
 
2.2.2 Cell freezing 
PBMCs were suspended in freezing media [RPMI-CM with 20% foetal calf serum 
(FCS) and 20% DimethylSufoxide (DMSO) (Sigma-Aldrich, UK)] on ice and 
aliquoted into cryovials and stored in -80 oC (max 1 week) before transfer to liquid 
nitrogen. 
 
2.2.3 Cell thawing 
Cryovials of PBMCs were transferred from liquid nitrogen on dry ice. Each vial was 
thawed in a water bath at 37 ºC. Once thawed  PBMCs were  transferred 
immediately to a 15 ml falcon tube containing 10 ml thawing media (RPMI 20% FCS 
containing 50,000 unit DNase). PBMCs were centrifuged at 1200 rpm for 10 min. 
PBMCs were then re-suspended in 1 ml media and cell count and viability were 
assessed. 
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2.3 In vitro culture 
PBMC were isolated from healthy subjects and suspended in RPMI 1640 medium 
(GIBCO, UK) supplemented with 10% FCS, gentamycin, and L-glutamine. Next, 
cells were distributed in flat-bottom 96 well-plate at 4 X 105 cells/well. Cells were 
then cultured at 37  C/5% Co2 for 5 consecutive days in the presence or absence of 
escalating dose of selected ABCB1 substrates (discussed later in sections 4.2.1 
and 4.2.2). Cells were either left un-stimulated or stimulated with anti-CD3/CD8 
beads (Dynabeads, Invitrogen, UK) according to the manufacturer‟s protocol (2μl 
beads / 8X104 cells).  Finally, cells were harvested on a daily bases and then 
prepared according to the required assay. In some experiments, in addition to 
abovementioned drugs, inhibitors of ABCB1 transport such as cyclosporine, 
PK11195 and vinblastine were added to the culture.  
 
For daunorubicin experiments, PBMC from healthy subjects chronically infected with 
CMV (CMV-seropositive) were used. Cells were then cultured in the presence or 
absence of 0.1 mM daunorubicin for 44–48 hr. Cells were then harvested, washed 
and prepared for further experiments.  
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2.4 Intracellular staining (Th1/Th2/Th17 and Foxp3) 
PBMCs were thawed and rested overnight at 37 ºC in 5% Co2, to minimize 
background cytokine production secondary to lymphocyte manipulation. PBMC were 
counted and plated at 5 x105 cells/ 200 µL RPMI supplemented with 10% FCS per 
well of a 96-well plate (BD FalconTM, Oxford, UK). Cells were stimulated using 4 
different conditions:  
1- No stimulation (negative control),  
2- PMA (50ng/ml)/Ionomycin (2µg/ml) (Sigma Aldrich),  
3- Anti-CD3/CD28 Dynabeads(Invitrogen) and  
4- CMV lysate (5µg/ml) or CMV pepmix (0.25 µg/ml) 
Brefeldine A (12.5 µg/ml) or monensin (Golgi-plug, Sigma Aldrich) was added for the 
last 4-6h of the culture. Next, cells were harvested, washed and stained with surface 
markers at RT for 15 min. Cells were then washed, fixed and permeabilized with 
eBioscience Foxp3 Staining Buffer Set (eBioscience, UK) and stained with FITC, PE 
and APC conjugated antibodies for intracellular markers (Table 2.1). Cells were 
acquired using BD FACSCalibur or BD LSRFortessa (BDbiosystem, USA) (Figure II-
2). Data analysis was performed on FlowJo software (Treestar, San Carlos, 
CA).Figure 2.1 shows an example of intracellular staining for cytokines and 
Foxp3 compared with their correspondent isotypes 
 
 
 
 
Table ‎2.1: Clones of Monoclonal antibodies used for intracellular staining 
 
Antibody Volume  Manufacturer (Clone) 
IFNγ 5 µl  BD ( 25723.11) 
IL-2 5 µl  BD (5344.111) 
IL-17 5 µl  eBiosciences (eBio64DEC17) 
TNFα 1 µl  BD ( MAb11) 
Foxp3 5 µl  eBiosciences (PCH101) 
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Figure ‎2.1: A representative example of intracellular staining. A, Gating strategy and 
cytokines staining; IL-2, TNFα, IFNγ and IL-17 were measured after stimulation with PMA 
and ionomycin. B, An example of Foxp3
+
 T cells staining.  Positivity was determined using 
isotype controls. 
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2.5 Comprehensive phenotypic analysis of T cell subsets using 
multi-colour flow cytometry 
I planned to comprehensively characterize T cell subsets in donor grafts, DLIs and 
PBMC collected from patients post-transplant, and relate the frequencies and 
functional phenotype of T cell subsets to the risk of GvHD post HSCT. The analyses 
were performed on BD LSRII and BD LSRFortessa, since both cytometers are 
equipped with 3-4 lasers, enabling detailed characterisation of T cell subsets using  
an extended (6-10 colours) antibody panel (Table. 2.2). Fluorochromes for the 
antibody panels were carefully selected to minimize fluorescence overlap. Briefly, 
freshly isolated or thawed PBMCs were stained with conjugated monoclonal 
antibodies (Mab) against a range of surface markers (as defined in Table 2.2) and 
incubated at room temperature for 10-20 minutes in the dark. Next, cells were 
washed with PBS or an equivalent staining buffer and spun for 5 minutes at 2000 
rpm. If the panel included an intracellular marker, I proceeded to fixing and 
permeabilisation followed by intracellular staining as shown in section 2.4.2. Cells 
were refrigerated until acquisition on the BD LSRII or LSRFortessa (BD biosystem, 
USA).  
Prior to acquisition, compensation was performed using BD compbeads plus (BD 
bioscience) to minimize overlap between fluorochromes as shown in Figure 2.2A. 
FlowJo (Treestar, San Carlos, CA) was used to analyse the data. Figure 2.2B 
shows an example of the gating strategy employed for the extended phenotypic T 
cell analysis. Following a lymphocyte gate, cell doublet and dead cell discrimination, 
I gated on live cells and the T cell subset of interest.  
To precisely determine the cut-off to discriminate the positive from the negative 
population, I employed fluorescence minus one (FMO). (Figure 2.2C). 
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Figure ‎2.2: A representative example of extended flow cytometric panel analysis. 
A, Compbeads were used to aid in setting up the compensation on the flow cytometer by 
gating on negative and positive peaks.B, gating strategy for the extended panel 
including lymphocyte gating, doublet exclusion and subset selection e.g. CD3
+
 CD4
+
 
CD45RA
+/-
 CD62L
+/-
 T cells. C, an example of fluorescence minus one for CD4 
monoclonal antibody, staining without (left) and with (right) CD4 antibody (FMO). 
 
 
 
CD
4
CD3
C) 
 Abdullah S. Alsuliman  PhD Thesis, 2013 
 
65 
Panel 
FL 
(Clone) 
Naïve / 
memory 
T- helper 
subsets 
 
 
Regulatory T 
cells 
Rhodamine 
123 efflux 
Refractory 
GvHD 
FITC CD31 
 
(WM59) 
IFNγ 
 
(25723.11) 
 CD161 
 
(DX12) 
Rh123 
 
- 
TCR γδ 
+
 
Vα24 TCR 
(11F2/C15) 
 5 µl 5 µl  10 µl 10µg/ml 10 µl / 5 µl 
PE Foxp3 
(PCH101) 
IL-4 
(MP4-25D2) 
 Foxp3 
(PCH101) 
CD25 
(2A3) 
CD25 
(2A3) 
 5 µl 10 µl  5 µl 5 µl 5 µl 
PerCP 
cy5.5 
CCR7 
(150503) 
IL-17 
(eBio64DEC17) 
 CD127 
(HIL-7R-M2) 
CD127 
(HIL-7R-M2) 
CD127 
(HIL-7R-M2) 
 3.5 µl 5 µl  3.5 µl 3.5 µl 3.5 µl 
APC CD45RO 
(UCHL1) 
IL-10 
(JES3-19F1) 
 CD25 
(M-A251) 
CD161 
(HP-3G10) 
CD161 
(HP-3G10) 
 5 µl 10 µl (1:14)  5 µl 5 µl 5 µl 
APC-H7 
(cy7) 
CD3 
(SK7) 
CD3 
(SK7) 
 CD3 
(SK7) 
CD4 
(RPA-T4) 
CD4 
(RPA-T4) 
 3 µl 3 µl  3 µl 3 µl 3 µl 
PE-cy7 CD4 
(SK3) 
CD4 
(SK3) 
 CD4 
(SK3) 
CD62L 
(DREG-56) 
CD62L 
(DREG-56) 
 2 µl 2 µl  2 µl 3 µl 3 µl 
Pacific 
blue 
- -  - CD95 
(DX2) 
CD95 
(DX2) 
     3 µl 3 µl 
Qdot 
605 
- -  - CD8 
(3B5) 
CD8 
(3B5) 
     1 µl 1 µl 
Qdot 
655 
- -  - CD45RA 
(MEM-56) 
CD45RA 
(MEM-56) 
     1 µl 1 µl 
Horizon 
V500 
- -  - CD3 
(UCHT1) 
CD3 
(UCHT1) 
     3 µl 3 µl 
Aqua Live/ Dead marker 
 
 1 µl 
 
Table ‎2.2: Antibodies, fluorochromes (FL), clones and volumes used in the 
extended phenotyping experiments. 
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2.6 In vitro efflux assays 
 
2.6.1 Rhodamine 123 efflux experiment 
Rhodamine 123 (Rh123) is a fluorescent dye, which easily crosses the plasma 
membrane. It can be visualized by a laser beam when excited at 505nm. This dye is 
the substrate of P-glycoprotein (P-gp), also known as ABCB1 transporter, a member 
of the ATP binding cassette (ABC) superfamily. Therefore, Rhodamine 123 can be 
used to study the efflux capacity of cells such as haematopoietic stem cells 
(Wagner-Souza et al. 2008).  
 
To perform this assay, freshly isolated PBMC are suspended in effluxing media 
(containing RPMI and 1% bovine serum albumin (BSA)) and incubated with 10µg/ml 
Rh123 (Sigma)  for 30 minutes on ice in the dark. Next, PBMC are washed with 
effluxing media at 1500 rpm for 10 minutes. To study the ability of the cells to pump 
the dye, the cells are divided into two tubes; one to be incubated for 30-60 minutes 
at 37C in 5% Co2,allowing the initiation of the efflux process and the other tube to be 
kept on ice to avoid spontaneous efflux of the dye. They are then washed with 
effluxing media and co-stained with surface antibodies to define the effluxing subset 
(Table 2.2). Rhodamine 123 fluorescence can be detected at 530/30 nm. Cells are 
acquired on FACSCalibur or LSRFortessa (for extended panel) and data analysed 
using FlowJo software. Figure 2.7a shows an example of CD4+ T cells, effluxing 
Rh123. 
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2.6.2 Daunorubicin efflux experiment 
Daunorubicin is a member of anthracycline family of chemotherapeutic agents. It is 
commonly used for remission induction in acute myeloid leukaemia (AML) patients. 
Naturally this substance has a fluorescent capacity when exposed to laser beam 
(blue or green laser) and thus, can be detected by flowcytometery.  Noteworthy, like 
rhodamine (section 2.6.1), daunorubicin is a substrate of the ABCB1 transporter. 
 
PBMC freshly isolated from healthy controls were suspended in effluxing media 
(containing RPMI and 1% BSA). Cells were then loaded with 2.5µM (1.4µg/ml) 
daunorubicin (Sigma Aldrich, UK) and incubated for 20 minutes at 37 °C in 5% Co2 
in the dark. Next, PBMC are washed with effluxing media at 1500 rpm for 10 minutes 
to remove the excess dye. The cells are then transferred into two tubes; one 
incubated at 37 °C in 5% Co2 in the dark for 30 minto allow the effluxing process to 
take place and the other was kept protected from light at RT as a negative control.  
Lastly, cells were washed with effluxing media and stained with surface antibodies 
(Table 2.3). Daunorubicin was excited using blue laser (488nm) and its fluorescence 
can be detected at 610/20 nm (PE-Texas Red). Cells were acquired on 
LSRFortessa (BD Biosystem, USA). 
 
FL 
 
PE-cy7  APC  PE-Texas Red APC-
H7 
 Pacific 
blue 
MoAb 
(Clone) 
CD4 
(SK7) 
 CD161 
(Hp-3G10) 
 Daunorubicin CD3 
(SK3) 
 CD95 
(DX2) 
volume 2ul  5ul   3ul  3ul 
 
Table ‎2.3: Antibodies, fluorochromes (FL), clones and volumes used in 
daunorubicin effluxing experiment 
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Figure ‎2.3: Representative experiment of in vitro effluxing assay. An example of 
effluxing experiment showing the ability of CD4
+
 T cells to pump out A, rhodamin123 or 
B, daunorubicin 
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2.7 Staining with 5-(and-6) 
carboxyfluoresceindiacetatesuccinimidyl ester (CFSE) for the 
proliferation assay 
 
5- (and -6)-carboxyfluoresceindiacetatesuccinimidyl ester (CFSE or CFDASE) dye 
has been widely used for the monitoring of in vivo lymphocyte migration as well as 
quantitative cell proliferation and divisions both in vitro and in vivo. Initially, this non-
fluorescent dye can cross the intact cell membrane. Subsequently, the acetate 
groups are cleaved by esterases inside the cells, which in turn generate the 
fluorescent carboxyfluorescein molecules. During proliferation, the CSFE-labelled 
dividing cells halve the carboxyfluorescein molecules within their daughter cells, 
resulting in CFSE dilution with each division (Lyons and Parish 1994;Parish 
1999;Parish et al. 2009;Weston and Parish 1990).  
 
I used CFSE (eBioscience, UK) to monitor the proliferation of T cells in response to 
in vitro stimulation with anti-CD3 /CD28 Dynabeads (Invitrogen). Briefly, freshly 
isolated PBMC (5X106/ 1ml) are labelled with 2µM CFSE (eBioscience, UK) 
suspended in DMSO (eBioscience, UK) and serum-free PBS, and incubated for 10 
minutes at room temperature (RT) in the dark. Equal volumes of neat FCS are then 
added for 5 minutes at RT/dark to stop the reaction. Next, PBMCs are centrifuged at 
2000 rpm for 5 minutes and the supernatant discarded. CFSE labelled PBMC are 
washed twice in serum containing media (RPMI + 20% FCS), re-suspended in FCS 
(10%) containing RPMI (GIBCO, invitrogen) and plated in a 96 well plate for 
subsequent stimulation. An example of the temporal kinetic of CFSE dilution in T 
cells following anti-CD3/CD28 stimulation is depicted in Figure 2.4. 
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Proliferation assays were carried out over 5 days; cells were harvested and washed 
with PBS following centrifugation at 2000 rpm for 5 minutes. Cells were then stained 
with a range of surface markers according to experimental protocol and acquired on 
a FACSCalibur flow cytometer (BD biosystems). 
 
Day 3
Day 4
Day 5
CFSE
Unstimulated Anti-CD3/28 beads
CFSE
 
Figure ‎2.4: An example of FACS plots showing CFSE-labelled CD4+ T cells before 
and after stimulation with anti-CD3/CD28 Dynabeads. The histograms demonstrate 
the kinetics of CFSE dilution within CD4
+
 T cells following: A, no stimulation (negative 
control), B, three days of stimulation, C. four days of stimulation and D, five days of 
stimulation. 
 
A B 
C 
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2.8 Apoptosis staining using Annexin V 
Apoptosis is the process of physiological programmed cell death, recognised by a 
number of morphological and intracellular features including loss of plasma 
membrane asymmetry, cytoplasmic and nuclear condensation and DNA 
fragmentation. One of the earliest characteristics of this process is the disrupted 
asymmetry of the plasma membrane, which results in the flipping of the negatively 
charged phospholipids, namely phosphatidylserine (PS), from the inner to the outer 
layer of cell membrane, thereby exposing PS to the external surroundings. Annexin 
V is a protein that binds to PS in a Ca2+ dependent manner. Therefore, 
fluorochrome-conjugated Annexin V can be used to visualise apoptotic cells using 
flow cytometry and, used together with a Live/dead marker such as propidium iodide 
(PI) or an equivalent, can discriminate apoptosis from necrosis at a single cell 
level(Tait et al. 1989;Vermes et al. 1995). 
 
To optimize the protocol for Annexin V staining, I treated freshly isolated PBMCs 
with escalating concentrations of test drugs for 5 days to induce apoptosis as shown 
in section 4.2.2.After culture, PBMC were washed, re-suspended in 500μl PBS, 
stained with 0.5 μL (1:1000) eflour660 live/dead dye (eBiosciences, UK). Cells were 
then incubated for 20 min at 4 °C, protected from light and then washed with PBS.  
PBMC were then washed again using 1X Annexin V washing buffer (BD bioscience, 
USA), prepared by diluting 10X Annexin V washing buffer with distilled water. This 
buffer is crucial for the assay as it contains Ca2+ required for the interaction between 
Annexin V and PS.  
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PBMC were then stained with 2µl of FITC-conjugated Annexin V (BD bioscience) 
along with surface antibodies including CD3, CD4 and CD161 (section 2.4.1) to 
identify apoptotic cells within each subset. PBMC were incubated for 20min at RT in 
the dark and washed in 2ml Annexin V washing buffer at 2000 rpm for 5 minutes. 
Lastly, cells were acquired on a FACSCalibur flow cytometry (BD biosystems). An 
example of Annexin V+ (apoptotic) cells within CD4+ T cells is shown in Figure 2.5 
 
Figure ‎2.5: Representative experiment of Annexin V staining. Gating strategy with 
an example of Annexin V percentage within CD4
+
 T cells are shown. 
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CHAPTER 3. STEM-LIKE CHARACTERISTICS IN A SUBSET OF   
CD161 EXPRESSING HUMAN MEMORY CD4+ T 
CELLS FACILITATES THEIR SURVIVAL AFTER 
CHEMOTHERAPY 
 
3.1 Introduction 
CD4+T cells play an indispensable role in shaping the adaptive immune system 
through their interaction with a variety of cells including B cells and CD8+T 
cells(Shedlock and Shen 2003;Sun et al. 2004). CD4+T cells are required for control 
of viral infection and play a significant role in the control of chronic viral infections 
such as protection against cytomegalovirus (CMV) disease(Salmon-Ceron et al. 
2000);(Pourgheysari et al. 2009). Several studies in animal models and humans 
have shown that the absence of CD4+T cell help results in severe dysfunction and 
failure of persistence of virus-specific CD8 T cells(Cardin et al. 1996;Kemball et al. 
2007;Lilleri et al. 2006;Lilleri et al. 2008;Matloubian et al. 1994;Walter et al. 
1995;Zajac et al. 1998).  Furthermore, the success of adoptively transferred CMV 
specific CD8+T cells in controlling infection post-transplant is largely dependent on 
the presence of anti-CMV CD4+T cells(Lilleri et al. 2006;Walter et al. 1995). 
 
The establishment of a wide range of long-lived pathogen-specific T cells, which are 
ready-to-act upon second encounter with the specific pathogen, is a fundamental 
property of the adaptive immune response. Following encounter with antigen, T cells 
proliferate vigorously in an antigen-specific manner. A subset of antigen-specific  
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memory T cells, with slow proliferative potential under normal homeostatic 
conditions, will persist for life.(Hammarlund et al. 2003);(Surh and Sprent 2008). The 
mechanisms employed by long-lived antigen-specific memory T cells for long-term 
persistence in humans are not clearly understood.  
 
Patients with acute myeloid leukaemia (AML) undergoing repetitive cycles of 
cytotoxic chemotherapy for remission induction experience severe, albeit short-lived 
lymphocytopaenia(Sung et al. 2009). Yet they rarely suffer serious viral reactivations 
such as CMV disease, supporting the existence of chemo-resistant populations of 
viral-specific memory CD8+ and CD4+T cells with the ability to self-renew and 
reconstitute immunity against infectious agents.  
 
The notion that a stem-like subset exists within the T cell repertoire has been clearly 
addressed in CD8+T cells. In mice, a postmitotic CD8+T cell subset with naïve 
phenotype (CD44loCD62Lhi) and self-renewal ability was found to differentiate into 
memory subsets and cause graft-versus-host disease (GvHD) upon transfer in a 
secondary host.(Zhang et al. 2005b) Similarly, Gattinoni and colleagues have 
recently described the homolog of this subpopulation in humans. These cells were 
defined as CD45RA+CD62L+ CD95+(Gattinoni et al. 2011), were enriched within the 
viral specific T cell population and exerted cytotoxic activity in a tumour model. 
Despite expressing naïve T cells markers, both subsets in mice and humans, were 
shown to exhibit stem cell signatures, including the expression of Sac-1 (only in 
mice), Bcl-2, IL-2Rβ and CXCR3(Gattinoni et al. 2005b). A recent study also 
reported the  
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existence of a memory subset of CD8+T cells (CD45RA- CD95+) with stem cell like 
properties, defined phenotypically on the basis of high expression of CD161 (NKR-
P1A), a marker primarily associated with natural killer (NK) cells(Lanier et al. 
1994b;Turtle et al. 2009). CD8+CD161hiT cells have the ability to rapidly efflux 
cytotoxic drugs through the ATP-binding cassette (ABC)–superfamily multidrug 
efflux protein ABCB1, shared expression of molecules with haematopoietic stem 
cells and were quiescent in non-lymphopenic individuals. A more recent study 
however, suggested that ABCB1+CD161hi CD8+T cells may in fact represent a 
subset of mucosal associated invariant T (MAIT) cells(Dusseaux et al. 2011) . 
Whereas much of our understanding of T cell memory has been attained through 
studies of CD8+T cells, recent studies have also suggested the existence of IL-17-
producing CD4+ (Th17) stem cell like cells(Kryczek et al. 2011;Muranski et al. 2011). 
 
Here I show the existence of a stem-like memory cells with high efflux capacity within 
the CD4+T cell compartment. I report that these CD4+T cells are enriched within the 
long-lived viral-specific Th1 memory T cell repertoire and share a similar phenotype 
to stem cell like memory CD8+CD161hiT cells. 
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3.2 Results 
 
3.2.1 CMV-specific CD4+ T cells survive induction chemotherapy in 
patient with AML 
CD8+ T cells specific for CMV, EBV, and influenza are detectable in patients with 
AML after recovery from chemotherapy(Turtle et al. 2009).I sought to investigate 
whether CD4+ T cells specific for CMV are also present in the PB of patients with 
AML following treatment with chemotherapeutic agents. PBMC from five AML 
patients collected at diagnosis and following recovery from induction chemotherapy 
with daunorubicin, a lymphocytotoxic ABCB1 substrate, were stimulated with a pool 
of overlapping MHC class II CMV pp65 peptides for 6 hr, and using IC cytokines 
analysis to look for IFNγ and TNFα production, the frequencies of CMV-specific 
CD4+ T cells were assessed directly ex-vivo. I found no significant difference in the 
frequencies of CMV-specific CD4+ T cells in AML patients at diagnosis compared to 
healthy controls. Following recovery from the first cycle of remission induction 
chemotherapy, there was a nearly fivefold increase (median 4.98, range 1.6-11.7) in 
the frequencies of CMV-specific CD4+ T cells in the PB of AML patients compared to 
diagnosis, p= 0.036. (Figures 1A and B), suggesting that a subset of CMV-specific 
memory CD4+ T cells might preferentially resist and therefore survive the 
lymphocytotoxic effect of daunorubicin.  
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Figure ‎3.1: CMV-specific CD4+ T cells in AML patients. A, a representative FACS plot 
depicting IFNγ-producing CMV-specific CD4+ T cells in an AML patient before (baseline) 
and after recovery from chemotherapy (remission). B, Significant fold increase in CMV 
specific CD4
+
 T cells in AML patients post-daunorubicin treatment (p=<0.036). 
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3.2.2 CMV specific CD4+ T cells have an effector memory phenotype 
and express CD161 
Multi-parameter flow cytometry was used to further characterize the phenotype of 
CMV-specific CD4+ T cells (Figure 2A). As expected, CMV-specific CD4+T cells fell 
within the memory T cell compartment, with high expression of CD95 and low 
expression of CD45RA and the adhesion molecule L-selectin (CD62L). CMV-specific 
CD4+ memory T cells from HD and AML patients (n=11) displayed significantly higher 
expression of CD161 (84.98 ± 2.7%), compared to only 33.83 ± 3.2% of the total 
CD4+ T population (p < 0.001) (Figures 2B and C). Such a profile is similar to that of 
viral-specific stem-like memory CD161+CD8+ T cells, reported to preferentially survive 
chemotherapy(Turtle et al. 2009).CD161 was also recently identified as a hallmark of 
Th17 cells(Cosmi et al. 2008). However, stimulation of PBMC from CMV seropositive 
donors with a pool of overlapping MHC class II CMV pp65 peptides failed to induce 
detectable IL-17 or IL-10 production, indicating that CMV-specific CD161+CD4+ T 
cells are in fact a unique subset of Th1,cells and are distinct from Th17 and Th2 cells. 
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Figure ‎3.2: Phenotypic characterization of CMV specific CD4+ T cells. PBMC were 
stimulated with an overlapping pool of MHC class II CMV pp65 peptides. Cells were 
gated on IFNγ-producing CD4+ T cells and examined for the co-expression of a panel of 
surface markers as outlined in Materials and Methods. A, A representative FACS plot 
showing the phenotype of IFNγ-producing CMV-specific CD4+ T cells (black) overlaid on 
total CD4
+
 T cells (grey) is presented. CMV-specific T cells are predominantly CD95
+
, 
CD45RA
-
, CD62L
-
 and CD127
+
.  B, A representative FACS plot showing that the 
majority of IFNγ+ and TNFα+ CMV-specific CD4+ T cells also express CD161. C, CD161 
expression on CMV specific CD4
+
 and total CD4
+
 T cells (p <0.001).  The majority of 
CMV specific CD4
+
 T cells co-express CD161. 
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3.2.3 CD161+CD4+ T cellsshare a similar phenotype with stem cell-like 
memory CD8+CD161hi T cells 
To characterize CD161+CD4+ T cellsfurther, freshly isolated PBMC from healthy 
controls (N=7) were stained with antibodies to CD16, TCR Vα24, CD8β, and γδ TCR 
to exclude NK, NKT, CD8dim and γδ T cells respectively, thereby allowing selective 
analysis of CD4+ and CD8+ T cells (Figure 3A). Whereas in CD8+ T cells, two 
populations of CD161 expressing T cells could be defined, a CD8+CD161hi and a 
CD8+CD161int subset, CD4+T cells displayed intermediate levels of CD161 
expression. CD4+CD161+(int) and CD8+CD161hi T cells shared remarkable phenotypic 
similarities, including high expression of CD127, CD95 and CD28 (Figure  3A). 
Using CD95 and CD45RA to distinguish memory cells from naïve T cells, and 
CD62L, CCR7 and CD28 to divide memory cells into central memory and effector 
memory cell subsets, CD4+CD161+ and CD8+CD161hi T cells were defined as 
memory T cells and were divided almost equally into effector and central memory 
subsets (Figure 3B). CD4+CD161+ memory T cells exhibited a significantly higher 
expression of CD127 compared to the total CD4+ T cell population (MFI 986.6 ± 120 
vs. 595.8 ± 61.7, p= 0.02) (Figure 3C). These cells also expressed CD25 (IL-2Rα), 
with the vast majority enriched within the CD25int population. Analysis of Foxp3 
expression as a marker for CD4+CD25+ regulatory T cells (Tregs) revealed that 
Tregs are in fact mainly confined to the CD4+CD161- T cell fraction and not the 
CD161+CD4+ T cell subset(Figure 3D). Overall, these data demonstrate that 
CD4+CD161+ are phenotypically very similar to the recently described CD8+CD161hi 
stem cell-like memory T cells (Figure 3A-C)(Turtle et al. 2009). 
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Figure ‎3.3Comprehensive phenotypic characterization of CD161
+
CD4
+
 T cells using 
multi-parameter flow cytometry. PBMC were stained with a panel of surface markers 
including anti-CD16, -TCR Vα24, -CD8β, and -γδ TCR to exclude NK, NKT, CD8dim and 
γδ T cells respectively. A. Cells were gated on CD4+CD161+ and CD8+ CD161hi stem-like 
memory T cells and analysed for expression of a panel of surface markers as defined in 
Materials and Methods. B, Multi-parameter analysis of gated CD161
+
CD4
+
 T cells 
identifies them to consist of a mixture effector (CD45RA
-
CD62L
- 
CCR7
-
) and central 
memory (CD45RA
-
CD62L
+
CCR7
+
) phenotype. C, histogram comparing the mean 
fluorescence intensity (MFI) of IL-7Rα (CD127) expression between CD161+ (solid line) 
and total CD4
+
T cell population (dashed line). D, A representative FACS plot comparing 
Foxp3 expression in CD4
+
CD161
-
(left) and CD4
+
CD161
+
(right) T cells is presented. 
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3.2.4 A subset of CD4+ CD161+T cell exhibit rapid multidrug efflux ability 
through ATP-dependent transporters and are resistant to daunorubicin 
lymphocytotoxicity 
Overexpression of ABC-superfamily multidrug efflux proteins is one mechanism by 
which haematopoietic stem cells resist chemotherapy(Chaudhary and Roninson 
1991) and was recently shown to play a role in the persistence of antigen-specific 
CD8+ memory T cells after chemotherapy(Turtle et al. 2009).I investigated the 
existence of a stem cell-like memory subset within the CD4+ T cell compartment by 
assessing ABCB1-mediated efflux of the fluorescent marker rhodamine-123 
(Rh123). Freshly isolated PBMC were incubated with Rh123 and, using multi-
parameter flow cytometry, a subset of CD4+ T cells with a rapid Rh123-effluxing 
capacity was identified (median 3.7%, range 2.5-5%)(Figure 4A). The rapidly 
effluxing CD4+ T cells were phenotypically very similar to the recently described 
CD8+ T cells with rapid Rh123-effluxing capacity(Turtle et al. 2009), including high 
expression of CD95, CD127 and CD161 (Figure 4B and C). I also found that the 
addition of vinblastine (a competitive inhibitor of ABCB1 and ABCC1), and other 
inhibitors with more specificity for ABCB1 such as cyclosporine A and PK11195, 
completely prevented or significantly reduced the efflux of Rh123 by CD4+ T (Figure 
4D)(Schinkel and Jonker 2003;Walter et al. 2004).Intriguingly, I also found a 
remarkable resemblance in the phenotype of Rh-123 effluxing CD4+ T cells and 
CMV-specific memory CD4+ T cells, namely, the uniform expression of CD95, low 
expression of CD62L and most specifically, the expression of CD161(Figures 2A 
and 4B, upper panel), suggesting that CMV-specific CD4+ T cells may also have 
high multi-drug efflux capacity. 
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I examined if CD161+CD4+ T cells are also capable of effluxing daunorubicin through 
the ABC-superfamily multidrug efflux proteins. Daunorubicin is a fluorescent 
anthracycline used for the treatment of AML which is effluxed through the same ABC 
transporters that efflux Rh123.  Memory CD4+CD161+CD95+ T cells were capable of 
rapidly effluxing daunorubicin and the efflux is completely blocked by the addition of 
ABCB1 and ABCC1 inhibitors (Figures 4E and 4F). 
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Figure ‎3.4: A subset of CD4
+
 T cells efflux Rhodamine123 and daunorubicin. PBMC 
were incubated with rhodamine123 for 30 to 60 minutes at 37oC and multicolour FACS 
analysis was performed on gated CD4
+
 Rh 123- (effluxing subset) and Rh 123
+
 (non-
effluxing subset). A, A representative FACS plot showing Rh123 efflux by CD4
+
 T cells 
after incubation at 37°C for 30-60min (right) compared with negative  control (left). B, 
histograms comparing the phenotype of Rh123
+
 (non-effluxing, right) and Rh123- 
(effluxing, left) subsets within CD4
+
 and CD8
+
 T cells. Rh123 effluxing CD4
+
 and CD8
+
 
subsets are enriched within the CD161
+
 effector memory (CD95
+
 CD45RA
-
 CD62L
-
) 
population. C, Histograms showing the increased expression of CD161 on Rh123-
effluxing CD4
+
 T cells relative to the total CD4
+
 T cell population (upper panel) and 
comparing CD161 expression on Rh123-effluxing CD4
+
 and CD8
+
 T cells (lower panel) 
are presented. D, FACS plots showing the abrogation of Rh123 efflux by CD161
+
CD4
+
 T 
cells following co-incubation with inhibitors of ABCB1 and ABCC1 (cyclosporine, PK11195 
and vinblastine). E, PBMC were co-incubated with fluorescent anthracycline 
(daunorubicin) for 30 to 60 min at 37oC. FACS plot shows daunorubicin efflux by CD4
+
 T 
cells and complete abrogation of efflux upon addition of  the ABCB1 inhibitors 
(cyclosporine A and PK11195) and ABCC1 (Vinblastine). F, Histograms show that the 
gated daunorubicin-effluxing CD4
+
 T cells (grey histogram) are enriched within the CD95
+
 
CD161
+
 memory T cell compartment compared to non-effluxing counterparts (white 
histogram). 
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3.2.5 A subset of CMV specific CD161+CD4+ T cellswith multi-drug efflux 
capacity are resistant to daunorubicin lymphocytotoxicity 
 
I next investigated if CMV specific CD161+CD4+ T cellshave high multi-drug efflux 
capacity and consequently, the capacity to survive daunorubicin, a fluorescent 
chemotherapeutic agent effluxed through the same ABC transporters that efflux 
Rh123. PBMC from CMV-seropositive healthy donors were incubated with 
daunorubicin for 44-48 hr in vitro. 
 
Using Annexin V staining, I found that daunorubicin induces apoptosis in both 
CD161- and CD161+ CD4+ T cell subsets; however, CD161+CD4+ T cells exhibit 
significantly greater resistance to the toxic effect of the drug (31.3%, ± 5.3 annexin 
V+) compared to their CD161- counterpart (46.7%, ± 5.9% annexin V+), p= 0.02 
(Figures 5A and B), supporting the existence of a drug-effluxing subset within the 
CD4+CD161+ T cells. Next, I compared the frequencies of CMV-specific CD4+ T cells 
(as assessed by IFNγ production following 6 hour stimulation with a MHC class II 
CMV peptide library pool) before and after 2 days of in vitro treatment with 
daunorubicin. I found a greater than 2-fold increase in the frequencies of CMV 
specific CD4+ T cells after 2 days of in vitro exposure to daunorubicin compared to 
baseline (0.16% ± 0.03 vs. 0.07% ± 0.01, p=< 0.011) (Figure 5C), supporting 
selective resistance of CMV-specific CD4+ T cells to the lymphocytotoxic effect of 
daunorubicin in vitro. 
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Figure ‎3.5: CMV-specific CD161+CD4+ T cells efflux daunorubicin and resist 
apoptosis following in vitro exposure to daunorubicinin vitro. PBMC were exposed 
to daunorubicin in vitro and apoptosis was assessed by annexin V staining. A, Histograms 
show the percentage of annexin V in CD4
+
CD161
-
 and CD4
+
CD161
+
. B, CD4
+
161
+
 T cells 
were significantly more resistant to apoptosis after 2 days of in vitro treatment with 
daunorubicin (p=0.02) as assessed by annexin V staining compared to their CD161
-
 
counterpart (n=6). C, Paired sample statistical analysis showing the preferential survival of 
CD4
+
CD161
+
 CMV-specific T cells (IFNγ-producing) after in vitro treatment with 
daunorubicin (p= 0.011). 
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3.2.6 CD161 expressing CD4+ T cells have a slow proliferation rate in 
vitro 
The long-term persistence of Ag specific memory T cell during normal homeostasis 
may be related to their slow proliferative rate. Indeed HSCs resist chemotherapy 
through a number of mechanisms related both to cell quiescence and the 
overexpression of ABC-superfamily multidrug efflux proteins(Chaudhary & Roninson 
1991;Li and Bhatia 2011). To evaluate the proliferative capacity of CD161+CD4+ T 
cells, I measured CFSE dilution after 5 days of polyclonal stimulation with anti-CD3/ 
CD28 beads in vitro. Similar to CD8+CD161+ stem like memory T cells, CD161+CD4+ 
T cells had a poorer proliferative capability compared to their CD161- counterpart 
(58.7% ± 5.1% vs. 91.6% ± 0.4%, p < 0.0001) (Figures 6 A-B).  
 
I next examined if under conditions of lymphopaenia-driven homeostasis, as seen 
following chemotherapy, the increased availability of cytokines such as IL-7, IL-15 or 
IL-21, can drive the proliferation of CD161+CD4+ T cells(Gattinoni et al. 2005).There 
was a significant increase in the absolute numbers of CD4+CD161+ and CMV 
specific CD161+CD4+ T cells in patients with AML recovering from daunorubicin-
based induction chemotherapy compared to their pre-treatment samples (174.5 ± 
28.3 vs. 89.5 ± 25.8 cells/μL, p= 0.026, and  2.6 ± 1.6 vs. 0.4 ± 0.2 cells/μL, p= 
0.0625, respectively), (n=3). These data suggest that CD161+CD4+ T cells with rapid 
efflux capacity survive chemotherapy in vivo and repopulate the memory 
compartment, thereby contributing to the maintenance of viral-specific memory after 
recovery from lymphocytopaenia. 
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Figure ‎3.6:Proliferation of CD4+CD161+ T cells. PBMC were loaded with CFSE and 
stimulated with anti-CD3/28 beads for 5 days. A, A representative histogram showing 
the relatively lower proliferative profile of CD4
+
CD161
+
 (grey histogram) compared to 
CD4
+
CD161
-
 T cells is presented (white histogram). B, Data from 8 experiments 
comparing CFSE dilution by CD4
+
CD161
+
 vs. CD4
+
CD161
-
 T cells. CD161 expressing 
CD4
+
 T cells have a significantly lower proliferative capacity compared to their CD161
-
 
counterpart (p <0.0001). 
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3.2.7 CD161 is a marker for long-lived Ag specific memory T cell 
To assess if CD161 is a marker of long-lived memory CD4+ T cells, I analysed the 
phenotype of Flu-specific CD4+ T cells in paired samples collected at 4 weeks and 2 
years following Flu vaccination in 4 healthy donors(de et al. 2011). Vaccination 
resulted in induction of Flu-specific CD4+ T cells in all healthy controls, as assessed 
by IFNγ production following overnight stimulation with or without seasonal influenza 
vaccine (A/Brisbane/59/2007(H1N1)in vitro. Although the frequencies of Flu-specific 
CD4+ T cells remained stable and were not significantly different at 4 weeks and 2 
years following vaccination (0.15 ± 0.05 vs. 0.21 ± 0.04 N=4, p=0.32) (Figure 7A), 
the proportion of Flu-specific CD4+ T cells that co-expressed CD161 was 
significantly greater at 2 years, compared to 4 weeks post-vaccination, (72.8 ± 3.1 
vs. 49.3% ± 3.5% p= 0.0046) (Figure 7B), suggesting that CD161 is a marker for 
long-lived viral-specific memory T cells. 
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Figure ‎3.7: Kinetic of Flu-specific CD161+CD4+ T cells following vaccination. PBMC 
collected from healthy donors 4 weeks and 2 years following influenza vaccination were 
stimulated in vitro with influenza antigen and IFNγ-producing CD4+ T cells were 
enumerated. A, a representative experiment to show the frequencies of IFNγ-producing 
Flu-specific CD4
+
 T cells before vaccination (left panel), 4 weeks (middle panel) and 2 
years (right panel) post-vaccination. B, IFNγ-producing Flu-specific CD4+ T cells have 
significantly higher expression of CD161 compared to the total CD4
+
 T cell population(*** 
p < 0.0001). The highest expression of CD161 is observed on Flu-specific CD4
+
 T cells 
2 years following influenza vaccination, (** p= 0.0046). 
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3.3 Discussion 
Following virus infection in immunocompetent individuals, Ag-specific T cells pass 
through three distinct phases: clonal expansion, contraction (also called the death 
phase), and memory(Kaech et al. 2002;Pepper and Jenkins 2011;Sprent and Surh 
2002).  Memory T cells confer immediate protection as well as the capacity to mount 
a more rapid and effective secondary immune response. Under circumstances where 
the immune system is compromised or destroyed, for instance following treatment 
with a number of lymphocytotoxic chemotherapeutic agents, patients still appear to 
be protected from viral infections. This strongly suggests that a number of 
mechanisms have evolved to maintain long-term T cell memory. A recent report 
described a distinct subset of human viral-specific stem-like memory CD8+ T cells, 
identified on the basis of their drug efflux capacity and distinct phenotype,(Turtle et al. 
2009) that persist after cytotoxic chemotherapy. Since CD4+T cells play an equally 
important role in viral immunity, I hypothesized that a similar subset of drug-effluxing 
CD4+ stem-like memory T cells may also exist.  
 
In this study the persistence of CMV-specific CD4+ T cell in the peripheral blood of 
patients with AML after recovery from remission induction chemotherapy was 
shown. Interestingly, CMV-specific CD4+ T cell frequencies after recovery from 
lymphocytotoxic chemotherapy were significantly higher than at presentation. 
Although it could be argued that the lower frequencies of CMV-specific CD4+ T cells 
in AML patients at diagnosis may be related to the underlying neoplasia(Costello et 
al. 2002;Le et al. 2009), their frequency and function (as assessed by their ability to 
produce IFNγ and TNFα following in vitro stimulation with an overlapping CMV 
peptide library) was not significantly different to that seen in healthy donors.  
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Therefore, it is likely that the proportional increase in CMV-specific CD4+ T cells after 
recovery from chemotherapy-induced lymphopaenia is related to their preferential 
survival and expansion.  
 
Multiple mechanisms including overexpression of ABC-superfamily multidrug efflux 
proteins and cell quiescence(Li & Bhatia 2011)  are employed by HSC (Chaudhary & 
Roninson 1991;Li & Bhatia 2011) as well as malignant cells (Dean et al. 2005;Li & 
Bhatia 2011) to resist chemotherapy. Similar mechanisms have also been reported 
to explain the persistence of stem-like CD8+ memory T cells after chemotherapy. In 
this study, I identified a sub-population of memory CD4+ T cells that were capable of 
effluxing the fluorescent substrate Rh123 as rapidly as CD8+ stem-like memory T 
cells.  Daunorubicin, a fluorescent anthracycline employed in the treatment of AML, 
is effluxed through the same ABC transporters that efflux Rh123. I showed that the 
high ABCB1-mediated drug efflux capacity of CD4+CD161+ memory T cells 
facilitates their resistance to daunorubicin and, that this resistance is abrogated by 
the addition of competitive inhibitors of ABCB1 and ABCC1(Schinkel & Jonker 
2003;Walter et al. 2004). 
 
The drug effluxing CD4+T cells in our study had a memory phenotype and were 
defined as CD95+, CD45RA-, CD127hi, CD28+, CD25int.  The majority of these cells 
also expressed CD161 (NKR-P1) primarily known as an NK marker(Lanier, Chang, 
& Phillips 1994b). However, whereas in CD8+ T cells two populations of CD161 
expressing T cells could be defined, a CD8+CD161hi and a CD8+CD161int subset, 
among CD4+ T cells, the proportion of CD161hi cells was very low and the 
expression of CD161 was at intermediate level. CD161+CD4+ T cells were 
phenotypically different from the naïve-like CD95 expressing T memory stem cells 
described by Gattinoni et al.(Gattinoni et al. 2011).I defined human memory stem-
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like CD4+ T cells on the basis of their drug efflux capacity, a property shared with 
HSCs, and used previously to define human memory stem-like CD8+ T 
cells(Chaudhary & Roninson 1991;Turtle et al. 2009). Interestingly, there is a 
remarkable phenotypic similarity between CD4+CD161int T cells with drug effluxing 
ability and the human CD8+CD161hi stem-like memory T cells described by Turtle et 
al(Turtle et al. 2009). Similar to their CD8+ counterpart, effluxing CD161+CD4+ T cells 
proliferated poorly in response to anti-CD3/CD28 stimulation in vitro, while 
propagating in response to homeostatic signals and repopulating the memory 
compartment in AML patients recovering from chemotherapy-induced 
lymphocytopaenia. A recent report that antigen-specific memory T cells express the 
anti-apoptotic marker Bcl-2,(Antoine et al. 2012) also involved in HSC survival, 
suggests that this subset of T cells may resist insult by cytotoxic agents through a 
number of mechanisms including drug efflux, low proliferative rate and expression of 
anti-apoptotic markers(Strasser et al. 1991;Strasser et al. 1994). 
 
Altogether, these results indicate that like HSC and CD8+ memory T cells, a subset 
of CD4+ memory T cells have drug-efflux capacity and are capable of surviving 
lymphocytotoxic insult. The identification of CD161 as a specific antigenic marker for 
stem-like memory CD4+as well as CD8+ T cells(Turtle et al. 2009) suggests a role for 
CD161 expressing T cells in long-term protection against pathogens. It is likely that 
CD161 expressing CD4+ T cells comprise a mixed cell population, some of which 
are endowed with stem cell like attributes. Indeed in our study only a subset of 
CD161+CD4+ T cells displayed Rh-effluxing capacity (Figure 4c).  CD161 was 
recently identified as a hallmark of Th17 cells.(Cosmi et al. 2008) CD161 is also 
expressed on MAIT cells(Dusseaux et al. 2011) and on a subset of CD8+ T cells with 
specificity for tissue localizing viruses such as hepatitis C and hepatitis B(Billerbeck 
et al. 2010).Here the enrichment ofCD161+CD4+ T cells are enriched within the 
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CMV-specific T cell repertoire in AML patients and normal controls was shown. 
Furthermore, in a cohort of healthy donors who mounted a CD4+ T cell response to 
vaccination with seasonal influenza, I observed that the proportion of CD161 
expressing Flu-specific CD4+ T cells increased over time. Upon stimulation with viral 
antigens, viral-specific CD161 expressing CD4+ T cells displayed a Th1 phenotype 
and failed to produce IL-17, indicating that these cells are in fact distinct from CD161 
expressing Th17 cells(Cosmi et al.  2008). 
 
 
Collectively, these results support a role for CD161+CD4+ T cells in the maintenance 
of long-lived memory to pathogens.  These data have significant implications for the 
development of the next generation of T cell based immunotherapies against 
pathogens and tumours. The long-term survival capacity of CD161 expressing T 
cells and their drug-effluxing capacity make them especially attractive for adoptive 
therapy against cancer. Thus, development of strategies to generate antigen-specific 
CD161 expressing stem cell like memory T cells might offer a highly effective 
approach to immunotherapy. 
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CHAPTER 4. DIFFERENTIAL EFFECT OF DEXAMETHASONE, 
CALCINEURIN INHIBITORS AND MTOR 
INHIBITORS ON CD161+CD4+ T CELLSAND 
FOXP3+CD4+ REGULATORY T CELLS 
 
4.1 Introduction 
A subset of antigen-specific memory CD8+ T cells with stem-like properties were 
recently described. This subset was capable of surviving cytotoxic drugs through 
mechanisms shared with haematopoietic stem cells, namely the expression of ATP 
binding cassette multidrug efflux proteins,(Chaudhary& Roninson 1991;Schinkel & 
Jonker 2003) and provided protection against infectious pathogens in AML 
patients(Turtle et al. 2009). Likewise, in chapter 3, I described the existence of a 
similar population within the memory CD4+ helper T cell compartment. Multidrug 
effluxing CD8+ and CD4+ T cells were defined by the expression of the NK cell 
marker CD161 (NKR-P1)(Lanier, Chang, & Phillips 1994b). 
 
 
ATP binding cassette (ABC) transporters belong to a superfamily of transmembrane 
proteins. By utilizing the ATP hydrolysis energy, these transporters facilitate the 
translocation of a variety of substrates including a number of drugs, across the 
plasma membrane.(Jones and George 2004) Almost fifty ABC transporters have 
been discovered so far and ABCB1, also known as P-glycoprotein, is one of the 
most extensively studied transporters.(Mizutani et al. 2008) This is the major 
transporter through which stem cells as well as cancer cells survive cytotoxic drugs 
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(Chaudhary & Roninson 1991;Gottesman et al. 2002).A wide range of inhibitors with 
different specificity for ABC transporters have been introduced(Falasca and Linton 
2012;Walter et al. 2004). Noteworthy, inhibition of the ABCB1 transporter has been 
exploited as a mechanism to overcome drug resistance in leukemic cells (Walter et 
al. 2004). 
 
Prior to allogeneic stem cell transplantation, patients undergo a preparative 
conditioning regimen which includes prophylaxis for GvHD such as calcineurin 
inhibitors(Nash et al. 2000). Moreover, once acute GvHD is diagnosed, 
corticosteroids are immediately used as a standard first line intervention to treat or at 
least ameliorate GvHD symptoms. However, a great proportion (~60%) of patients 
fails to respond to corticosteroids(MacMillan et al. 2002;Martin et al. 1990;Van Lint et 
al. 2006) necessitating second line treatment(Benito et al. 2001;Hoda et al. 2010). 
Of note, some of the drugs used for the prevention or treatment of GvHD, including 
corticosteroids, are substrates for ABC transporters(Schinkel & Jonker 2003). 
 
 
In this chapter I hypothesise that CD161+CD4+ T cells will efflux immunosuppressive 
drugs used for GvHD prophylaxis and treatment using the MDR pump complex. 
Thus, steroid-refractory GvHD could be explained by the ability of this subset of 
helper T cells to escape the lymphocytotoxic effect of these drugs. I also test if the 
addition of ABC transporter inhibitors T cells treated with steroids will induce further 
apoptosis in vitro. 
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4.2 Results 
 
4.2.1 Selection of P-glycoprotein (ABCB1) substrates 
First, three different drugs which are primarily used in GvHD prophylaxis or 
treatment were selected including calcineurin inhibitors e.g. tacrolimus (Tacro), 
mTOR inhibitors e.g. rapamycin (Rapa) and corticosteroids e.g. dexamethasone 
(Dex) (all from Sigma Aldrich, UK). These drugs mediate their immunosuppressive 
activity through different modes of action. Tacrolimus and rapamycin inhibit T cell 
proliferation whereas corticosteroid (e.g. dexamethasone) are lymphocytotoxic and 
induce apoptosis(Distelhorst 2002). All these three drugs are substrates of ABCB1 
multidrug efflux transporter(Schinkel & Jonker 2003). Since the mode of action for 
each drug is different, I first evaluated the optimal in vitro conditions for their use.  
 
 
4.2.2 Titration of drugs (ABCB1 substrates); Dexamethasone, 
Tacrolimus, and Rapamycin 
Dose titration experiments for Dexamethasone, Tacrolimus, and Rapamycin were 
performed to determine the optimal dose for in vitro T cell proliferation and viability 
assays.   Since each drug has a different mode of action, Annexin V and CFSE 
assays were used to measure apoptosis (cell death) and proliferation, respectively. 
Titration experiments were done on PBMC from three healthy controls. 
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PBMC were incubated with or without anti-CD3/CD28 beads (Dynabeads, 
Invitrogen, UK) in the presence or absence of the test drugs at different 
concentrations for 5 days (120 hours). T cell proliferation and viability were assessed 
on a daily basis. 
 
4.2.2.1 Dexamethasone (Dex):  
Dexamethasone is a glucocorticoid with anti-inflammatory properties. In addition, it is 
lymphocytotoxic and induces apoptosis in T lymphocytes as well as lymphoid 
leukaemia cells(Distelhorst 2002;Frankfurt and Rosen 2004;Herold et al. 
2006).Generally, it is more potent than prednisolone, which is widely used in the 
transplant clinic to treat GvHD symptoms(Van Lintet al. 2006). 
 
To determine the impact of dexamethasone on T cell viability and proliferation, 
PBMC were incubated with increasing concentrations of dexamethasone in vitro; 10-
6, 10-5 and 10-4 M (Blauer et al. 1991;Orlikowsky et al. 2001)and daily Annexin V and 
CFSE assays for 5 days were performed(Figures 4.1 and 4.2). I determined that, 
using the conditions outlined above, day three (Day 3) is the optimal time to 
measure dexamethasone-induced T cell apoptosis (Figure 4.3A).  
 
Dexamethasone induced apoptosis in CD4+ T cells when compared to the negative 
control at 3 tested concentrations (Figure 4.1 and 4.3B) and suppressed T cell 
proliferation in a dose dependant manner as depicted by CFSE staining (Figure 
4.2). Based on these preliminary data, I chose a dexamethasone dose of 10-5 M (10 
μmol/L “μM” ~ 3.9μg/ml) as the concentration to be used in my in vitro experiments. 
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4.2.2.2 Rapamycin (Rapa): 
Rapamycin (also known as Sirolimus) exerts its immunosuppressive activity through 
inhibition of the mTOR (mammalian target of rapamycin) pathway. Unlike calcineurin 
inhibitors, which inhibit IL-2 secretion, rapamycin prevents T cell proliferation through 
inhibiting the response to IL-2.mTOR inhibitors are occasionally prescribed as 
second line intervention for steroid-refractory aGvHD(Dignan et al. 2012). In 
accordance with previously published in vitro studies that used rapamycin at 
concentrations ranging from 0.1 to 10 μM, I evaluated three concentrations of 
rapamycin in my experiments including 0.1, 1 and 10 μM(Uss et al. 2007). 
 
As expected, there was no significant difference in the proportion of apoptotic cells 
(Annexin V+) in CD4+ T cells treated with or without rapamycin (Figure 4.1 and 
4.3A); however, at the concentration of 10 μM, rapamycin was more likely to be toxic 
to T cells. In contrast, all 3 concentrations inhibited CD4+ T cell proliferation as 
assessed by CFSE assay, (Figure 4.2). Therefore, I selected a rapamycin 
concentration of 0.1 μM to avoid non-specific drug toxicity.  
 
4.2.2.3 Tacrolimus (Tacro): 
Tacrolimus (also known as FK506) is a member of calcineurin inhibitors. It interferes 
with T cell activation through inhibition of  IL-2 transcription and signal 
transduction(Thomson et al. 1995).In AHSCT, Tacrolimus is commonly used in 
GvHD prophylaxis(Dignan et al.  2012). Concentrations used for in vitro experiments 
range from 1 to 25 ng/mL (1 to 30 nM)(Uss et al. 2007). Therefore, I examined 
tacrolimus  
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activity at 1, 10 and 50 nM. The induction of apoptosis by tacrolimus was minimal 
when compared with no treatment control (Figure 4.1 and 4.3A). On the other hand, 
its ability to inhibit T cell proliferation was most significant at a dose of 25-50 nM 
(Figure 4.2). Therefore, I chose a tacrolimus dose of 25nM of for my subsequent 
experiments. 
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Figure ‎4.1: A representative drug titration (apoptosis experiment)(n=3) Fresh 
PBMCs were cultured for 5 days in the presence or absence of different concentrations of 
immunosuppressive drugs. Dotplots showing induction of apoptosis in CD4
+
 T cells in 
response to different concentrations of dexamethasone, rapamycin and tacrolimus. 
Apoptosis was measured by Annexin V and Live/Dead staining (eflour660). 
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Figure ‎4.2: A representative drug titration (proliferation experiment) (n=3).Fresh 
PBMCs were cultured for 5 days in presence or absence of different concentrations of 
immunosuppressive drugs. Histograms showing the proliferation of CD4
+
 T cells using 
CFSE staining in presence or absence of different concentrations of dexamethasone, 
rapamycin and tacrolimus. 
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Figure ‎4.3: Apoptosis induction by drug treatment (n=5) A, PBMC were cultured for 
5 days in the presence or absence of dexamethasone (red line), rapamycin (blue line), 
tacrolimus (green line) or no drug (black line) and apoptosis was evaluated using 
Annexin V staining. Results are presented as mean ±SEM. Two way ANOVA was used 
(p= <0.0001). B, Bar chart showing Annexin V
+
 apoptotic cells within CD4
+
 T cells after 
three days of culture with or without dexamethasone at different concentrations; all 3 
concentrations of dexamethasone induced apoptosis of CD4+ T cells (p=ns). (p=ns). 
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4.2.3 CD161+CD4+ T cells are more resistant to drug-induced apoptosis 
than CD161- T cells. 
In the previous chapter (section 3.2.4), I showed that CD161+CD4+ T cells are 
capable of effluxing drugs through the ABC multidrug efflux proteins. This property 
gives this subset of CD4+ T cells the ability to survive the lymphocytotoxic effect of 
some chemotherapeutic agents such as daunorubicin. To investigate if 
immunosuppressive drugs also act as ABCB1 substrates, I examined the ability of 
CD161+CD4+ T cells to survive the lymphocytotoxic effect of these drugs. 
Dexamethasone induced significant apoptosis of unstimulated CD4+ T cells, 
measured by Annexin V staining compared with the negative control (16.2% ± 2.6% 
vs. 7.3% ± 1.9%, p=0.034) (Figure 4.4 A). However, CD161+CD4+ T cells appeared 
to exhibit more resistance to the lymphocytotoxic effect of dexamethasone 
compared to their CD161- counterpart, although the difference did not reach 
statistical significance(9% ± 1% vs. 11% ± 1.1%, p= 0.092) (Figure 4.4 B). In 
contrast, tacrolimus and rapamycin did not induce significant apoptosis in CD4+ T 
cells compared to the negative control (6% ± 0.8% vs. 7.3% ± 1.9%; p=0.55and 
10.3% ± 1.8 vs. 7.3% ± 1.9%; p=0.3, respectively) (Figure 4.4 A).  
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Figure ‎4.4: Percentage of Annexin V+ apoptotic cells (n=5). A, Dot chart showing 
Annexin V
+
 apoptotic cells within CD4
+
 T cells in the presence or absence of 
dexamethasone (* p=0.034), rapamycin and tacrolimus. B, Dot chart showing the 
difference in Annexin V percentage (apoptosis) between CD161
+
CD4
+
 T cells and their 
CD161
-
 counterparts in response to dexamethasone (p=0.092). One way ANOVA was 
used to test significance. 
 
 
ND Dex Rapa Tacro
0
5
10
15
*
ns
ns
Treatment
P
e
rc
e
n
t 
o
f 
A
n
n
e
x
in
 V
+
CD4+CD161+ CD4+CD161-
0
5
10
15
20 p= 0.092
ns
P
e
rc
e
n
t 
o
f 
A
n
n
e
x
in
 V
+
A 
B 
 Abdullah S. Alsuliman  PhD Thesis, 2013 
 
109 
4.2.4 CD161+CD4+ T cells proliferate preferentially in the presence of 
Dexamethasone and Tacrolimus, but not Rapamycin 
I next examined the impact of dexamethasone, tacrolimus and rapamycin on the 
frequencies of CD161+CD4+ and CD161-CD4+T cells following anti-CD3/CD28 
stimulation. I calculated the percentage increase inCD161+CD4+ T cells following 
stimulation using the following formula: 
 
   (                      
                       
)            
 
A selective expansion ofCD161+CD4+ T cells was observed when stimulated with 
anti-CD3/28 in the presence of dexamethasone when compared to negative (no 
drug) control (percentage increase 31.3% ± 17.8 vs. -21% ± 7.9%, p= 0.018). 
Likewise, in the presence of tacrolimus I saw a selective induction ofCD161+CD4+ T 
cells (percentage increase 23.6% ± 3% vs. -21% ± 7.9%, p= 0.0001). In contrast, I 
did not observe a significant impact of rapamycin on the proliferation of CD161+CD4+ 
T cells in culture (percentage increase -15% 6.8% vs. -21% 7.9%,p=ns) (Figure 
4.5A and B).  
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Figure ‎4.5:  Representative experiment of CD161
+
CD4
+
 T cells expansion (n=8). PBMC 
were stimulated with anti-CD3/28 beads for 5 days in the presence or absence of 
dexamethasone, rapamycin and tacrolimus. A, Dot plots showing the percentage of 
CD161
+
CD4
+
 T cells after 1 and 5 days of culture in the presence or absence of 
dexamethasone, rapamycin and tacrolimus. Percentage increase was calculated by dividing 
the percentage of CD161
+
CD4
+
 T cells at day 5 (right panel) by the frequencies of 
CD161
+
CD4
+
 T cells at baseline (left panel). B, Bar chart showing the percentage increases 
in CD161
+
CD4
+
 T cells in response to drugs treatment. Results were shown as mean ± SEM. 
One way ANOVA was used. 
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I next investigated if CD4+CD161+ T cells have a greater ability to survive and 
expand in the presence of immunosuppressive drugs compared to their CD161- 
counterpart. I therefore calculated the CD161+CD4+ T cell proliferation ratio for each 
condition by dividing the percentage of CD4+CD161+CFSE
lo
 cells by CD4+CD161-
CFSE
lo
 at day 5 in the presence or absence of the drug. In keeping with previously 
published data (Turtle et a. 2009), I found that in the absence of drugs, CD4+CD161+ 
T cells stimulated with anti-CD3/CD28 have an inherently slower proliferative 
response than CD4+CD161- T cells (section 3.2.6), i.e. they are more quiescent. 
However, in the presence of dexamethasone, CD161+CD4+T cells proliferated more 
significantly than CD161- CD4+T cells compared to no drug control (1.17 ± 0.15 vs. 
0.85 ± 0.08, p= 0.045). This phenomenon was even more pronounced in the 
presence of tacrolimus(1.26 ± 0.14, p= 0.015) but not rapamycin (0.9 ± 0.04, p=0.2) 
(Figure 4.6 A&B), suggesting that CD161+ CD4+ T cells, through their rapid effluxing 
properties, may have the ability to resist these drugs in vitro.  
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Figure ‎4.6: Representative CD4
+
 T cells proliferation assay (n=5).A, Histograms 
showing the difference in proliferation between of CD4
+
CD161
+
 (Pink) and CD161
-
 (Blue) 
T cells in absence (ND) or presence of dexamethasone (Dex), rapamycin (Rapa) and 
tacrolimus (Tacro). Proliferation ratio was calculated by dividing the percentage of 
CD161
+
CFSE
-
 by CD161
-
CFSE
-
. B, Bar chart showing the difference in proliferation ratio 
in presence or absence of dexamethasone, rapamycin and tacrolimus. Results were 
shown as mean ± SEM. One way ANOVA was used to test significance. 
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4.2.5 IFNγ-production CD161+CD4+ T cells selectively expand in the 
presence of Rapamycin 
 
The role of IFNγ-producing T cells (helper T cells type1 “Th1”) in GvHD has been 
contradictory (Ferrara, Levine, Reddy, & Holler 2009;Yang et al. 1998). However, 
their contribution to the onset of acute GvHD has been well described(Ferrara and 
Reddy 2006;Fowler et al. 1994;Nikolic et al. 2000). Takahashi and colleagues have 
recently shown that CD4+ T cells co-expressing CD161+ produce more 
IFNγ(Takahashi, Dejbakhsh-Jones, & Strober 2006). Therefore, I examined whether 
the proliferating population of CD161+CD4+ T cells also produce more IFNγ in the 
presence of Dex, Tacro or Rapa.  
 
To address this, PBMC were stimulated with anti-CD3/28 beads in the presence or 
absence of the selected drugs for 5 days. The kinetics of IFNγ-
producingCD161+CD4+ T cell expansion in the presence or absence of 
dexamethasone, rapamycin and tacrolimus were assessed on a daily basis (Figure 
4.7B). The fold increase in IFNγ-producingCD161+CD4+ T cell was calculated by 
dividing the percentage of IFNγ+CD161+CD4+ T cells at day 5 by IFNγ+CD161+CD4+ 
T cell at baseline. Treatment with dexamethasone did not have a significant impact 
on the expansion of IFNγ+CD161+CD4+ T cells compared to no drug control (Fold 
increase0.9 ± 0.09 vs. 1.24 ± 0.16, p=0.12). As expected, tacrolimus impaired IFNγ 
production by CD161+CD4+ T cells compared to controls (Fold increase 0.3 ± 0.07 
vs. 1.24 ± 0.16, p=0.0001). Rapamycin on the other hand, facilitated the selective 
expansion of IFNγ-producingCD161+CD4+ T cells(Fold increase1.8 ± 0.17 vs. 1.24 ± 
0.16, p= 0.027) (Figure 4.7 A&C).   
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Figure ‎4.7:IFNγ production by CD161+CD4+ T cells in the presence or absence of 
dexamethasone, rapamycin and tacrolimus (n=8).A, Dot plots showing the percentage 
of CD4
+
CD161
+
 IFNγ+ T cells after 1 and 5 days of culture. Fold increase was calculated 
by dividing the percentage of CD4
+
CD161
+IFNγ+ at day 5 (lower panel) by 
CD4
+
CD161
+IFNγ+ at baseline (pre-expansion) (upper panel).  B, Line chart showing the 
time-based change in the percentage of CD4
+
CD161
+IFNγ+ T in response to drug 
treatment.  C, Dot chart showing the fold increase in IFNγ-producingCD161+CD4+ T cells 
in presence or absence of GvHD drugs. Results are shown as mean ± SEM. Two and one 
way ANOVA was used to test significance. 
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4.2.6 IL-17 producing CD161+CD4+ T cells selectively expand in the 
presence of Dexamethasone and Rapamycin, but not Tacrolimus 
CD161+CD4+ T cells were recently shown to be the precursor of IL-17-producing 
cells, (Th17)(Cosmi et al. 2008). Additionally, recent studies have discussed the role 
of Th17 cells in GvHD pathogenesis(Bossard et al. 2012;Dander et al. 
2009;Ratajczak et al. 2010). Therefore, I examined whether the significant increase 
in the frequencies of CD161+CD4+ T cells in the presence of dexamethasone and 
tacrolimus, is associated with an increase in IL-17 production.  
 
The frequency of IL-17-producing CD161+CD4+ T cells was measured using 
intracellular flow cytometry. Figure 4.8 A&B shows the sequential change in the 
frequencies of IL-17-producing CD161+CD4+ T cells in vitro following anti-CD3/CD28 
stimulation in the presence or absence of immunosuppressive drugs. I calculated the 
fold increase in IL-17-producing CD161+CD4+ T cells after stimulation with anti-
CD/CD28 beads for 5 days compared to baseline. Interestingly, there was a 
significant fold increase in IL-17-producing CD161+CD4+ T cells in the presence of 
dexamethasone compared to no drug control (5.2 ± 0.7 vs. 1.9 ± 0.3, p=0.0008).  
 
Similarly, there was a significant fold increase in IL-17-producing CD161+CD4+ T 
cells in the presence of rapamycin compared to no drug control (4.4 ± 0.9 vs. 1.9 ± 
0.3, p=0.022). In contrast, tacrolimus impaired IL-17 production in CD161+CD4+ T 
cells compared to the no drug control group (0.37 ± 0.07vs. 1.9 ± 0.3, p=0.0002) 
(Figure 4.9). These data suggest that IL-17 producing CD4+CD161+ T cell have to 
ability to proliferate and expand in the presence of immunosuppressive and 
lymphocytotoxic agents such as rapamycin and corticosteroids. 
 Abdullah S. Alsuliman  PhD Thesis, 2013 
 
116 
 
Figure ‎4.8IL-17 production by CD161
+
CD4
+
 T cells in the presence or absence of 
dexamethasone, rapamycin and tacrolimus (n=8). A, Dot plots showing the percentage of 
CD4
+
CD161
+
IL-17
+
 T cells after 1 and 5 days of culture. Fold increase was calculated by 
dividing the percentage of CD4
+
CD161
+
IL-17
+
 T cells at day 5 (right panel)  CD4
+
CD161
+
IL-
17
+
 T cells  percentage at baseline (Day 0) (left panel).  B, Line chart showing the kinetics of 
CD4
+
CD161
+
IL-17 T cell expansion in response the presence or absence of dexamethasone, 
tacrolimus or rapamycin. Results are shown as mean ± SEM. Two way ANOVA was used to 
test significance. 
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Figure ‎4.9Fold increase in IL-17-producing CD161
+
CD4
+
 T cells(n=7). Dot chart 
showing the fold increase in IL-17-producing CD161
+
CD4
+
 T cells in presence or absence 
of dexamethasone, rapamycin and tacrolimus. Results are shown as mean ± SEM. One 
way ANOVA was used to test significance. 
 
 
4.2.7 Dexamethasone induces a reduction in CD4+Foxp3+ regulatory T 
cells 
Regulatory T cells have indisputably established their role in immune tolerance. In 
AHSCT, for instance, Foxp3+ Treg has been demonstrated in several human and 
murine studies to play a key role in preventing GvHD occurrence (section 1.5).In 
addition, disruptions in the ratio of Treg/Teff correlate with GvHD onset and severity.  
 
The preferential expansion of CD4+CD161+IL-17-producing T cells in the presence 
of dexamethasone led me to question whether this might impact on the balance 
between Th17 and Treg cells. To address this question, the frequencies of 
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The fold increase in CD4+Foxp3+ T cells was calculated by dividing CD4+Foxp3+ T 
cells at day 5 by frequencies at baseline. After 5 days of culture, the frequencies of 
CD4+Foxp3+ T cells did not change significantly in the absence of co-incubation with 
immunosuppressive drugs. Co-incubation with rapamycin had only a minor impact 
on CD4+Foxp3+ T cells compared to no drug control (0.72 ± 0.07 vs. 1.3 ± 0.08, 
p=ns). In contrast, in the presence of dexamethasone there was a significant 
reduction in the frequencies of CD4+Foxp3+ T cells compared to no drug control (fold 
increase 0.09 ± 0.01 vs. 1.3 ± 0.08, p< 0.0001).Likewise, tacrolimus reduced the 
frequencies of CD4+Foxp3+ T cells (fold increase 0.53 ± 0.13 vs. 1.3 ± 0.08, p< 
0.05)(Figure 4.11). This reduction in Treg frequencies is likely due to 
dexamethasone-induced apoptosis of Tregs. These data suggest that 
dexamethasone may have a detrimental effect on CD4+Foxp3+ T cells in vitro and 
possibly in vivo. 
 Abdullah S. Alsuliman  PhD Thesis, 2013 
 
119 
 
Figure ‎4.10: Representative FACS plot depicting Foxp3 expression on total CD4
+
 T 
cells. Dot plots showing the percentage of CD4
+
Foxp3
+
 T cells after 1 and 5 days of in 
vitro culture with or without dexamethasone, rapamycin and tacrolimus. 
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Figure ‎4.11:Expression of Foxp3 in the presence or absence of dexamethasone, 
rapamycin and tacrolimus (n=8). A, Line chart showing the time-based change in the 
percentage of CD4
+
Foxp3
+
 T cells presence of dexamethasone (red line), rapamycin 
(blue line), tacrolimus (green line) and no drug (black line). B, Dot chart showing the 
fold increase in the expression of Foxp3 on CD4
+
 T cells in the presence or absence of 
dexamethasone, tacrolimus or rapamycin. Results were shown as mean ± SEM. Two 
and one way ANOVA were used to test significance, respectively. 
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4.2.8 ABCB1 and ABCC1 inhibitors synergise with Dexamethasone to 
induce apoptosis of CD161+CD4+ T cells and reduce IL-17 production 
 
I have formerly described in section 3.2.4 the drug-effluxing ability of CD161+CD4+ 
T cells through the ABCB1 transporter. Since dexamethasone is a substrate of 
ABCB1, I hypothesized that blocking these transporters using the previously 
mentioned ABC transporter inhibitors (cyclosporine, vinblastine and PK11195) may 
inhibit the efflux of dexamethasone byCD161+CD4+ T cells and induce their 
apoptosis. To test this hypothesis, PBMC were cultured for 1, 3 and 5 days in the 
presence or absence of dexamethasone with or without the ABCB1 and ABCC1 
inhibitors. Cells were either un-stimulated or stimulated with anti-CD3/28 beads.  
 
The percentage of apoptotic cells in CD161+CD4+ T cells in the different culture 
conditions was examined. As shown in Figure 4.12, whereas the specific inhibitors 
of ABCB1, PK11195 and cyclosporine, both failed to increase dexamethasone-
induced apoptosis, the addition of vinblastine, a competitive inhibitor of ABCB1 and 
ABCC1, to the culture significantly enhanced dexamethasone-induced apoptosis 
after 5 days of co-culture, p = 0.037, suggesting that both ABCB1 and ABCC1 may 
be involved in efflux of dexamethasone in CD161+ CD4+ T cells. 
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Figure ‎4.12:Apoptosis induction by drug treatment (n=3) Line chart showing the 
kinetics of drug-induced apoptosis in the absence(no drug, black line) or presence of 
dexamethasone (red line)with or without cyclosporine (CsA)(blue line), PK11195 
(PK)(grey line) (ABCB1 inhibitor) and vinblastine (Vin)(green line) (ABCB1 and ABCC1 
inhibitor). Results are presented as mean ± SEM. Two way ANOVA was used to test 
significance.  
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dexamethasone was demonstrated earlier in section 4.2.4. I sought to examine if 
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proliferate in the presence of dexamethasone(-24.5% ± 6.2 vs. 31.3% ± 17.8, 
p=0.049),supporting the notion that CD4+CD161+ T cells may overcome the 
immunosuppressive effect of dexamethasone by effluxing the drug through ABCB1 
and ABCC1 transporters. 
 
Figure ‎4.13:Change in the percentage of CD4+ CD161+ T cells in the presence of 
dexamethasone and ABC transporter inhibitors(n=3). Bar chart showing the 
percentage proliferating CD161
+
CD4
+
 T cells in co-culture in the presence of 
dexamethasone, with or without cyclosporine, PK11195 and vinblastine. Percent 
increase was calculated by dividing the percentage of CD4
+
CD161
+
 at day 5 by 
percentage of CD161
+
CD4
+
 T cells at day 0. Results were presented as mean ± SEM. 
One way ANOVA was used to test significance. 
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Similarly, PK11195 inhibited the ability of CD161+CD4+ T cells to produce IL-17 in 
the presence of dexamethasone; however insignificantly (2.1% ± 0.8 vs. 4.7% ± 0.77 
with dexamethasone alone, p= 0.09) (Figure 4.14).  
 
 
Figure ‎4.14:Fold increase in IL-17-producing CD161+CD4+ T cells(n=3). Bar chart 
showing the fold increase in IL-17-producing CD161
+
CD4
+
 T cells in presence or absence of 
dexamethasone with or without cyclosporine, PK11195 and vinblastine. Percent increase 
was calculated by dividing the percentage of CD4
+
CD161
+
 IL-17
+
 at day 5 by CD4
+
CD161
+
 
IL-17
+
 at day 0. Results are shown as mean ± SEM. One way ANOVA was used to test 
significance. 
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I showed in section 4.2.5 that there is no impact of in vitro culture with 
dexamethasone on the ability of CD161+CD4+ T cells to produce IFNγ (Figure 4.7). 
Similarly, there was no significant effect of ABC transporter inhibition on IFNγ-
producingCD161+CD4+ T cells(Figure 4.15). 
 
 
Figure ‎4.15:Fold increase in IFNγ-producingCD161+CD4+ T cells(n=3). Bar chart 
showing the fold increase in IFNγ-producingCD161+CD4+ T cells in presence or absence 
of dexamethasone with or without cyclosporine, PK11195 and vinblastine. Percentage 
increase was calculated by dividing the percentage of CD4
+
CD161
+
 IFNγ+ at day 5 
CD4
+
CD161
+
 IFNγ+ at day 0. Results were shown as mean ± SEM. One way ANOVA 
was used to test significance. 
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Finally, I checked if dexamethasone-induced reduction of Tregs can be reversed by 
co-culture with ABC transporter inhibitors. PBMC were cultured in the presence of 
dexamethasone for 5 days with or without ABC inhibitors and the frequencies of 
Tregs were assessed by Foxp3 staining. The addition of cyclosporine A and 
PK11195 inhibitors (specific ABCB1 inhibitors) did not significantly affect the 
frequencies of Tregs compared to dexamethasone alone, suggesting that these cells 
may not have the machinery for rapid drug efflux. Similarly, the addition of 
vinblastine (ABCB1 and ABCC1 competitive inhibitor) to dexamethasone did not fully 
restore Foxp3+CD4+T cell frequencies to control levels (0.5 ± 0.2 vs. 1.32 ± 0.08, p= 
0.001)(Figure 4.16).  
Figure ‎4.16:Expression of Foxp3 on CD4+ T cells in the presence or absence of 
dexamethasone with or without cyclosporine, PK11195 and vinblastine. (n=3). Bar 
chart showing the fold increase in the expression of Foxp3 on CD4
+
 T cells. Percent 
increase was calculated by dividing the percentage of CD4
+
Foxp3
+
 T cells at day 5 
CD4
+
Foxp3
+
 T cells at day 0. Results are shown as mean ± SEM. One way ANOVA was 
used to test significance. 
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4.3 Discussion 
 
Acute GvHD is the most frequent complication of AHSCT and it is mediated by the T 
cell content in the donor graft(Shlomchik 2007). A number of pharmacological 
approaches, mainly targeting T cells, have been employed to control this deleterious 
outcome(Dignan et al. 2012). In this study, I showed that, in keeping with the 
findings in chapter 3, CD4+CD161+ T cells can resist apoptosis induction by 
lymphocytotoxic agents in vitro. Notably, this resistance was associated with an 
alteration in their functional profile. The fact that these drugs are known to be 
substrates of ABC transporters may explain this phenomenon. 
 
Corticosteroids remain the mainstay for the treatment of acute GvHD(Deeg 2007).  A 
previous study reported the existence of a population of steroid-resistant CD4+ T 
cells within the CD4+CD25int T cell compartment. These cells had the ability to 
proliferate when co-cultured with steroids in vitro(Lee et al. 2007). In keeping with 
this study, I showed that whereas dexamethasone induced apoptosis and impaired 
CD4+ T cell proliferation in vitro, a subset of CD4+ T cells co-expressing CD161 
exhibited more resistance to the lymphocytotoxic effect of dexamethasone in 
vitro.CD161+CD4+ T cells in my study had an effector memory phenotype (Chapter 
3) and were enriched within the CD25int population. In accordance with these data, I 
herein further characterized the population of steroid resistant T cells, based on 
CD161 co-expression. The surviving CD161+CD4+ T cells were characterised by IL-
17, but not IFNγ production, suggesting that these cells are in fact Th17 cells. As 
shown in Chapter 3, CD161 expression is a marker for rapidly-effluxing memory T  
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cells. Since dexamethasone is a substrate of the ABC transporter complex 
(Gottesman, Fojo, & Bates 2002), it is likely that the preferential survival and 
proliferation of CD161+CD4+ T cells in the presence of dexamethasone in vitro could 
be a consequence of rapid drug efflux by CD4+CD161+ T cells. Moreover, 
dexamethasone induced a reduction in the frequency of CD4+Foxp3+ regulatory T 
cells. These data further support my hypothesis that steroid refractoriness may be, 
at least partly, governed by the ability of a subset of Th17 cells to efflux steroids 
through the ABC transporter complex. As the majority of CD4+Foxp3+ T cells are 
CD161-, they are unlikely to exhibit drug efflux ability, which may in turn explain their 
increased susceptibility to dexamethasone treatment in vitro. Based on my data and 
in keeping with previous studies, steroid treatment may affect the balance between 
Th17 and regulatory T cells. These data suggest a role of CD4+CD161+IL-17+ T cells 
in steroid-refractory GvHD.   
 
Tacrolimus, a calcineurin inhibitor, is used for GvHD prophylaxis following allogeneic 
stem cell transplantation. In this study, I showed that tacrolimus inhibited the 
proliferation of CD4+CD161- T cells to a greater extent than CD4+CD161+ T cells, 
suggesting that CD161+CD4+ T cells may efflux tacrolimus through the MDR pump. 
As expected, tacrolimus inhibited the production of IFNγ and IL-17 with no significant 
difference in the CD161+ and CD161- populations. Unlike dexamethasone, 
tacrolimus did not affect the survival of Foxp3+ Treg, indicating that a mechanism of 
action of this drug may be through shifting the balance of Th17/Treg ratio towards 
tolerance induction.  
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Rapamycin has been used as a second line treatment for steroid-refractory GvHD 
with some success. In my study rapamycin inhibited proliferation of CD161+ and 
CD161- CD4+ T cells to the same extent, suggesting that rapamycin may not be 
effluxed to the same extent by CD4+CD161+ T cells. Furthermore, rapamycin did not 
impact on Treg frequencies in vitro. A previous study suggested that rapamycin 
favours the expansion of regulatory T cells and prevents the differentiation of T cells 
towards a Th17 phenotype(Battaglia, Stabilini, & Roncarolo 2005;Coenen et al. 
2007;Kopf et al. 2007).  Altogether, these data suggest that rapamycin may exert 
activity in aGvHD through maintenance of regulatory T cells and inhibiting the 
proliferation of CD161+CD4+ T cells.   
 
Blocking ABC transporters has been exploited as a strategy to overcome the 
resistance of cancer cells to chemotherapeutic agents(Walter et al. 2004). Here, I 
used inhibitors of ABCB1 and ABCC1 to minimize the efflux of dexamethasone by 
CD4+CD161+ T cells, and hence, overcome the steroids refractoriness of these cells. 
The addition of these inhibitors resulted in a reduction in IL-17 production 
fromCD4+CD161+ T cells. Whereas the specific inhibitors of ABCB1, PK11195 and 
cyclosporine, both failed to increase dexamethasone-induced apoptosis, the addition 
of vinblastine, a competitive inhibitor of ABCB1 and ABCC1, to the culture 
significantly enhanced dexamethasone-induced apoptosis after 5 days of co-culture, 
suggesting that both ABCB1 and ABCC1 may be involved in dexamethasone efflux 
by CD4+CD161+ T cells. Interestingly, the addition of inhibitors did not reverse 
dexamethasone-induced reduction in the frequencies of regulatory T cells, 
suggesting that these cells may not have the machinery for rapid drug efflux.  
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Overall, these data support the use of ABC transporters inhibitors in combination 
with steroids to overcome the resistance of CD161+CD4+ T cells to corticosteroids 
and to restore the effector/regulatory balance in an attempt to overcome steroid-
refractory GvHD. 
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CHAPTER 5. RATIONALE FOR THE COMBINATION OF 
CORTICOSTEROIDS WITH CALCINEURIN AND 
mTOR INHIBITORS 
 
5.1 Introduction 
In chapter 4I studied the in vitro effect of immunosuppressive drugs namely, 
dexamethasone, tacrolimus and rapamycin, all of which are ABCB1 substrates, on T 
cell subsets(Table 5.1).  
 
Table 5.1: Summary of the effect of co-culture with dexamethasone, rapamycin 
and tacrolimus on the frequencies of CD4
+
 CD161
+
 T cells, Th17 and Tregs in vitro. 
 
 
Tacrolimus minimizes the risk of graft rejection in solid organs transplantation (Anon 
1994;Woodle et al. 1996) and is used for GvHD prophylaxis in stem cell 
transplantation(Nash et al. 1996). Tacrolimus is better tolerated than cyclosporine in 
the AHSCT setting as the latter appears to confer more nephro- and neuro-
toxicity(Nash et al. 1992). 
Parameter Dexamethasone Rapamycin Tacrolimus 
CD4+ CD161+ 
%
IL-17
IFNγ
FoxP3
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Corticosteroids are the standard first line treatment for acute GvHD(Deeg 2007).  In 
clinical practice, aGvHD patients who fail to respond to steroids within three to five 
days of treatment are considered steroid-refractory. In fact, only 35% to 40% of 
patients with aGvHD will have a complete response to steroids, underscoring the 
need for developing alternative treatment strategies for steroid-refractory 
aGvHD(MacMillan et al. 2002;Martin et al. 1990;Van Lint et al. 2006). Concomitant 
tacrolimus and steroid treatment was reported to be beneficial,  mainly, in patients 
with mild to moderate GvHD (Dignan et al. 2012). Tacrolimus was also shown to be 
effective for the treatment of steroid-refractory GvHD(Kanamaru et al. 1995;Koehler 
et al. 1995). 
 
The mTOR inhibitor, rapamycin, also known as sirolimus, is an immunosuppressant 
that is used as a second line treatment for aGvHD if steroids are unsuccessful(Benito 
et al. 2001;Ghez et al. 2009;Hoda et al. 2010).  Studies on sirolimus alone as a first 
line intervention for aGvHD have shown comparable responses to that achieved with 
high doses of steroids(Pidala et al. 2011). 
 
A number of studies have also explored the combination of these drugs for GvHD 
prophylaxis. A recently published study showed the feasibility of combining 
prednisolone with tacrolimus and methotrexate, as graft-versus-host disease 
prophylaxis in non-T cell-depleted haplo-identical transplant recipients(Mochizuki et 
al. 2011). In this study, no patient experienced grade IV GvHD, while all patients who 
developed aGvHD responded to steroid treatment. Recently, the combination of 
sirolimus and tacrolimus with or without ATG showed promising results for GvHD 
prophylaxis(Khaled et al. 2012;Ringden et al. 2011). 
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These studies support a role for combining these drugs for the prevention or 
treatment of aGvHD in vivo. 
 
The aim of this chapter was to investigate the in vitro effect of combining steroids 
(dexamethasone), calcineurin inhibitors (tacrolimus) and mTOR inhibitors 
(rapamycin) on proliferation and cytokine profile of CD4+CD161+ and frequencies of 
regulatory T cells (CD4+Foxp3+). 
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5.2 Results 
 
5.2.1 Combinations of dexamethasone, tacrolimus and rapamycin 
induce variable effects on CD161+CD4+ T cell proliferation in vitro 
Using a CFSE assay, I assessed the proliferation and frequencies of CD161+CD4+ T 
cells co-cultured in vitro in the presence of a combination of dexamethasone, 
tacrolimus or rapamycin. The percentage increase of CD161+CD4+ T cells was 
calculated using the following formula: 
 
   (                      
                       
)            
 
Firstly, I found that the combination of dexamethasone and tacrolimus inhibited the 
expansion of CD161+CD4+ T cells significantly more than dexamethasone 
(percentage increase 7.4% ± 4.4% vs. 31.3% ± 17.7%., p=0.05) or tacrolimus alone 
(percentage increase 7.4% ± 4.4% vs. 23.6% ± 3%, p= 0.009) (Figure 5.1A). This 
effect is largely due to the ability of this combination to control the proliferation of 
both CD161+ and CD161- CD4+ T cells (Figure 5.1B).  
 
Next, the combination of dexamethasone with rapamycin was assessed. This 
combination did not induce any significant drop in the frequencies of CD161+CD4+ T 
cells compared to dexamethasone alone (percentage increase 20.5% ± 6.2% vs. 
31.3% ± 17.7%, p= 0.7) although there were more proliferating CD161+CD4+ T cells 
compared to cultures with rapamycin alone (percentage  increase20.5% ± 6.2%vs.  -
15.6% ± 6.8%, p= 0.015) (Figure 5.1 A&B).  
 Abdullah S. Alsuliman  PhD Thesis, 2013 
 
135 
Finally, I assessed the effect of combining tacrolimus and rapamycin on the 
frequencies and proliferation of CD4+CD161+ and CD161- T cells. This resulted in a 
significant drop in the frequencies of CD161+CD4+ T cells compared to tacrolimus 
alone (percentage increase -1.35% ± 7.7% vs. 23.6% ± 3%, p=0.004) (Figure 5.1A). 
However, the impact of this combination on the proliferation of CD161+ and CD161- 
CD4+ T cells was not significant (Figure 5.1B), suggesting that the drop in the 
frequencies resulted from both CD161+ and CD161- proliferating at the same rate. 
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Figure ‎5.1:The effect of drug combinations on the viability and proliferation of 
CD161
+
CD4
+
 T cells(n=3). A, Bar chart showing the percentage increase in 
CD161
+
CD4
+
 T cells in response to drugs combinations. B, Histograms showing the 
difference in proliferation between CD4
+
CD161
+
 (Pink) and CD161
-
 (Blue) T cells. 
Results are presented as mean ± SEM. One way ANOVA was used. 
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5.2.2 Combinations of dexamethasone, tacrolimus and rapamycin 
prevent IL-17 production by CD4+CD161+ T cells 
In the previous chapter, I reported that tacrolimus successfully inhibits the production 
of IL-17 by CD161+CD4+ T cells, whereas rapamycin and dexamethasone fail to 
suppress IL-17 production by CD161+CD4+ T cells. Here, I evaluated the effect of 
combining dexamethasone, tacrolimus or rapamycin on CD4+CD161+IL-17-
producing T cells. I calculated the fold increase in IL-17-producing CD161+CD4+ T 
cells by dividing the percentage of IL-17+CD161+CD4+ T cells at day 5 by IL-
17+CD161+CD4+ T cells at baseline. I found that the combination of tacrolimus with 
dexamethasone resulted in a significant reduction in the percentage of IL-17-
producing CD161+CD4+ T cells compared to dexamethasone alone (fold increase 
0.05 ± 0.02 vs. 5.2 ± 0.7, p=0.0013). Similarly, the combination of rapamycin and 
dexamethasone resulted in a significant decrease in IL-17-producing CD161+CD4+ T 
cells(fold increase 2.75 ± 0.5%)  compared to dexamethasone alone (fold increase 
5.2 ± 0.7%; p=0.03) and rapamycin alone (fold increase 4.4 ± 0.9, p= 0.14).  The 
frequency of IL-17-producing CD161+CD4+ T cells in response to this combination 
was comparable to the no drug control (fold increase 2.75 ± 0.5 vs. 1.9 ± 0.3%, 
p=0.18), (Figure 5.2 B). Lastly, the combination of  tacrolimus with rapamycin 
synergized to significantly lower the percentage of IL-17-producing CD161+CD4+ T 
cells compared to rapamycin alone or no drug control (fold increase 0.26 ± 0.07 vs. 
4.4 ± 0.9; p= 0.018 and 1.9 ± 0.3, p=0.006, respectively)(Figure 5.2 C).  
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Figure ‎5.2:Percentages of IL-17-producing CD161+CD4+ T cells following co-
culture with combinations of dexamethasone, tacrolimus or rapamycin (n=3). A, 
Bar chart showing the fold increase in IL-17-producing CD161
+
CD4
+
 T cells in response 
to Dex/Tacro (A), Dex/Rapa (B) and Rapa/Tacro (C). Fold increase was calculated by 
dividing the percentage of IL-17-producing CD161
+
CD4
+
 T cells at day 5 on theirs at the 
beginning of the experiment. Results were shown as mean ± SEM. One way ANOVA 
was used to test significance 
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5.2.3 Combinations of dexamethasone, tacrolimus and rapamycin 
prevent IFNγ production by CD4+CD161+ T cells 
 
I demonstrated in the previous chapter that the frequencies of IFNγ-
producingCD161+CD4+ T cells increase when co-cultured with rapamycin in vitro, 
but not with tacrolimus or dexamethasone (section 4.2.3). Therefore, I evaluated the 
effect of combinations of dexamethasone, tacrolimus or rapamycin on 
CD4+CD161+IFNγ-producing T cells. I calculated the fold increase in IFNγ-
producingCD161+CD4+ T cell by dividing the percentage of IFNγ+CD161+CD4+ T 
cells at day 5 by IFNγ+CD161+CD4+ T cell at baseline. In keeping with the findings 
outlined above, I found that the combination of tacrolimus with dexamethasone 
resulted in significant reductions in the percentage of IFNγ-producingCD161+CD4+ T 
cells compared to dexamethasone or no drug control  (fold increase 0.06 ± 0.02 vs. 
0.93 ± 0.09; p= 0.0005, and 1.24 ± 0.16 p=0.002, respectively).    
 
Next, I combined dexamethasone with rapamycin and found that, in contrast to co-
culture with rapamycin alone where I reported a selective increase in IFNγ-
producingCD161+CD4+ T cells(section 4.2.3), the drug combination reduced IFNγ 
production in CD161+CD4+ T cells to a level similar to the no drug control (fold 
increase 1.27 ±0.2 vs.1.24 ± 0.16, p=0.9) (Figure 5.3 B). Similarly, combining 
tacrolimus with rapamycin reduced IFNγ production in CD161+CD4+ T cells 
compared to rapamycin alone (fold increase 0.59 ± 0.38 vs. 1.8 ± 0.17, p=0.007). 
(Figure 5.3 C). 
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Figure ‎5.3: Frequencies of IFNγ-producingCD161+CD4+ T cellsfollowing co-culture  
with dexamethasone, tacrolimus or rapamycin (n=3).Bar charts showing the fold 
increase in IFNγ-producingCD161+CD4+ T cells in response to Dex/Tacro (A), Dex/Rapa 
(B) and Rapa/Tacro (C). Fold increase was calculated by dividing the percentage of IFNγ-
producing CD4
+
CD161
+
 at day 5 by IFNγ-producing CD4+CD161+ at baseline. Results 
were shown as mean ± SEM. One way ANOVA was used. 
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5.2.4 The addition of tacrolimus or rapamycin to dexamethasone does 
not prevent dexamethasone-induced decrease in CD4+Foxp3+ regulatory 
T cell  
 
I reported in section 4.2.6 that dexamethasone might induce apoptosis in regulatory 
(Foxp3+CD4+) T cells (Figure 5.3). Here, I evaluated whether the addition of 
tacrolimus or rapamycin to dexamethasone will impact on CD4+Foxp3+ T cell 
frequencies in vitro. The fold increase in CD4+Foxp3 T cells was calculated by 
dividing CD4+Foxp3+ T cells frequencies at day 5 by their frequencies at baseline. 
 
The addition of tacrolimus or rapamycin to dexamethasone did not prevent 
dexamethasone-induced reduction in Tregs frequencies (fold increase in Treg 
frequencies following culture 0.07 ± 0.01 vs. 0.09 ± 0.1, p=0.2) and (0.1 ± 0.05 vs. 
0.09 ± 0.1, p=0.66) respectively. Moreover, the combination of rapamycin and 
tacrolimus was also highly suppressive to Tregs compared to no drug control (fold 
increase 0.34 ± 0.12vs. 0.72 ± 0.06, p=0.018). 
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Figure ‎5.4:Frequencies of Foxp3+ CD4+ T cells in the presence of drugs alone or in 
combination (n=3). Bar charts show the fold increase in CD4
+
Foxp3
+
 T cells in 
response to dexamethasone/tacrolimus (A), dexamethasone/rapamycin (B) and 
rapamycin/ tacrolimus (C). Fold increase was calculated by dividing the percentage of 
CD4
+
 Foxp3
+
 at day 5 by frequencies at baseline. Results were shown as mean ± SEM. 
One way ANOVA was used. 
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5.3 Discussion 
A number of different prophylactic regimens are used to prevent GvHD following 
allogeneic stem cell transplantation. However, in a significant proportion of patients, 
these regimens might fail to protect against GvHD(Deeg 2007). I demonstrated in 
chapter 4 that CD161+CD4+ T cells might play a role in the pathogenesis of steroid-
refractory aGvHD and also showed that the 3 different groups of immunosuppressive 
drugs (steroids, calcineurin inhibitors and mTOR inhibitors) have differential effects 
on CD4+CD161+ T cells. Therefore, I hypothesized that through their different 
mechanisms of action, combinations of these drugs may have a synergistic effect to 
suppress CD4+CD161+ T cells. Overall, I demonstrated in this study the advantage of 
combining dexamethasone with tacrolimus or rapamycin in suppressing CD161+CD4+ 
T cell proliferation and IL-17 production.  
 
Clinical data supports the use of steroids in combination with calcineurin 
inhibitors(Dignan et al. 2012). In addition, Mochizuki et al recently showed that the 
addition of steroids to tacrolimus and methotrexate in the haplo-identical stem cell 
transplantation setting reduces the severity of GvHD and increases the response to 
steroids treatment(Mochizuki et al. 2011). In accordance with these studies, I showed 
that the combination of dexamethasone and tacrolimus effectively prevents the 
expansion of CD4+CD161+and CD161-CD4+T cells. Moreover, I also demonstrated 
that the addition of tacrolimus to dexamethasone significantly reduces the production 
of pro-inflammatory cytokines such as IL-17 and IFNγ by CD4+CD161+ T cells. 
Interestingly, the suppression of CD161+CD4+ T cell proliferation and cytokine 
production were not associated with increased apoptosis. 
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Interestingly, the combination of these drugs had deleterious effect on Foxp3+ 
regulatory T cells. A number of studies have shown that Tregs appear to be highly 
sensitive to CD95L-induced apoptosis, in contrast to their more resistant Teff 
counterparts.(Fritzschinget al. 2005;Krammeret al. 2000). In vivo, the apparent 
selective sensitivity of Treg to CD95L might be a mechanism to eliminate Treg during 
the acute effector phase of an immune response at a time when Teff are resistant to 
CD95-mediated apoptosis. However, this same phenomenon may also contribute to, 
and exacerbate, GVHD. 
 
Rapamycin has been reported to induce durable responses, similar to responses 
achieved with steroids when used as a “first-line” treatment for aGvHD(Pidala et al. 
2011). Rapamycin has also been used as second line treatment for steroid-
refractory aGvHD. However, the efficacy of rapamycin alone compared to rapamycin 
plus dexamethasone has not been formally addressed. In addition, the combination 
of dexamethasone and rapamycin has been shown to induce apoptosis in leukemic 
cells both in vitro and in vivo(Gu et al. 2010). In this study, I showed that the 
combination of dexamethasone and rapamycin induced apoptosis within the 
CD161+CD4+ T cell population. Although the drug combination did not significantly 
suppress the proliferation of CD4+CD161+ T cells, it inhibited the production of IFNγ 
and IL-17 by CD4+CD161+ T cells.  
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In these experiments, I also demonstrated that the combination of rapamycin and 
tacrolimus is highly effective at reducing the production of IFNγ and IL-17 by 
CD4+CD161+ T cells. However, this combination did not suppress the proliferation of 
CD161+ and CD161- CD4+ T cells.  
 
These data support the use of combinations of immunosuppressive drugs with 
different modes of action for prophylaxis and the treatment of aGvHD. 
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CHAPTER 6. ASSESSMENT OF CD161+CD4+ T CELL 
FREQUENCIES AND FUNCTION IN PATIENTS 
WITH STEROID-REFRACTORY AND STEROID-
RESPONSIVE ACUTE GVHD 
 
6.1 Introduction 
 
Acute GvHD is the most frequent complication after stem cell transplantation. Donor 
allo-reactive T lymphocytes play a significant role in its initiation and 
propagation(Shlomchik 2007). The occurrence of acute GvHD varies from10% to 
80% according to risk factors and prophylaxis regimens used prior to SCT(Deeg 
2007). High doses of systemic corticosteroids are the first-line therapy of choice for 
aGvHD (Dignan et al. 2012).  However, steroid therapy fails to resolve GvHD in a 
significant proportion of patients(MacMillan et al. 2002;Martin et al. 1990;Van Lint et 
al. 2006).  So far, the pathophysiology of steroid-refractory GvHD is not well defined. 
 
The role of T cells in the refractoriness and resistance to steroids has been 
demonstrated in a number of autoimmune diseases. In keeping with the findings 
presented in Chapter 4, Lee and colleagues reported the presence of a subset of 
steroid-resistant CD4+ T cells in uveitis patients.(Lee et al. 2009a)The same group in 
a separate publication showed that these cells have intermediate expression of CD25 
(CD25int)(Lee et al. 2007).  Interestingly, mAbs against the IL-2 receptor (anti-CD25) 
have been used as second-line therapy in patients with refractory aGvHD, suggesting 
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that CD4+CD25int T cells may play a role in the pathogenesis of steroid-refractory 
aGvHD  (reviewed in (Dignan et al. 2012)).  
 
It has been shown that steroids promote the switch from Th1 (IFNγ and IL-2) to Th2 
(IL-4 and IL-10) phenotype through inhibition of IL-12 production by macrophages 
and dendritic cells(Blotta et al. 1997;Franchimont et al. 1998).Reports on the effect of 
steroids on Th17 cells have been conflicting ;a recent murine study of airway 
inflammation, reported that steroid resistance is mediated by Th17 cells(McKinley et 
al. 2008). 
 
In this chapter I aim to examine the role of CD161+CD4+ T cells in steroid-refractory 
aGvHD by analysing the frequency and function of these cells in patients with steroid-
refractory and steroid-responsive aGvHD. The hypothesis is that, in keeping with the 
in vitro experiments presented in chapter 4, CD4+CD161+ IL-17+ T cells will be 
expanded in the peripheral blood of patients with steroid-refractory aGvHD compared 
to patients with steroid-responsive or no GvHD. 
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6.2 Results 
 
6.2.1 Patients characteristics and timing of peripheral blood sampling 
 
Twenty one patients who underwent haematopoietic stem cells transplantation at the 
Hammersmith hospital between 2009 and 2011 were studied. PBMC samples were 
collected pre- and post-transplantation at days 30, 45, 60, 90 and 120 days following 
stem cell infusion. PBMC were processed as outlined in section 2.2. PBMC samples 
collected just before or at the time of GvHD diagnosis and after or during steroid 
treatment were examined. Patients were divided into three groups; No acute GvHD 
(n=8), steroid-responsive (SRs) (n=6) and steroid-refractory acute GvHD (SRf) 
(n=7)(Table 6.1). Acute GvHD was graded in the transplant clinic following the 
modified Seattle Glucksberg criteria.  
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Table ‎6.1: Characteristics of stem cell transplantation patients. Patients were sub-
divided according to GvHD occurrence and response to steroids. 
  
All                                        
(N=21) 
No acute 
GvHD   
(N=8) 
Steroid-
responsive 
acute 
GvHD 
(N=6) 
Steroid-
refractory  
acute 
GvHD 
(N=7) 
    number (percent)   
Median age in years                    
(range) 
49                                                           
(25-66) 
50    
(25-64) 
60                                                           
(26-64) 
47                                            
(41-66) 
Sex         
 Male 15 (71.4) 6 (75) 4 (66.7) 5 (71.4) 
 Female 6   (28.6) 2 (25) 2 (33.3) 2 (28.6) 
Diagnosis         
 Acute leukaemia 5 (23.8) 3 (37.5) 1 (16.7) 1(14.3) 
 Chronic myelogenous leukaemia 4 (19) 2 (25) 0 (0) 2 (28.6) 
 Malignant lymphoma 9 (42.9) 2 (25) 4 (66.6) 3 (42.8) 
 Others 3 (14.3) 1 (12.5) 1 (16.7) 1 (14.3) 
Conditioning regimen         
 Myeloablative conditioning 7 (33.3) 1(12.5) 4 (66.7) 2 (28.6) 
 Reduced intensity conditioning 14 (66.7) 7 (87.5) 2 (33.3) 5(71.4) 
Stem cell donors         
 Related 7 (33.3) 2 (25) 2 (33.3) 3 (42.9) 
 Unrelated 14 (66.7) 6 (75) 4 (66.7) 4 (57.1) 
HLA Match         
 HLA-identical 20 (95.2) 7 (87.5) 6 (100) 7 (100) 
 HLA-mismatched 1 (4.8) 1 (22.5) 0 (0) 0 (0) 
Stem cell source         
 Bone Marrow 1 (4.8) 1 (22.5) 0 (0) 0 (0) 
 Peripheral Blood Stem Cells 20(95.2) 7 (87.5) 6 (100) 7 (100) 
Post-transplant 
immunosuppressive prophylaxis         
 Cyclosporine-Methotrexate 11(52.4) 4 (50) 0 (0) 6 (85.7) 
 Cyclosporine-Methotrexate-ATG 7 (33.3) 2 (25) 5 (83.3) 1 (14.3) 
 Cyclosporine-Methotrexate-Campath 3 (14.3) 2(25) 1 (16.7) 0 (0) 
Acute GVHD         
 Grades I-II 5(23.8) 0 (0) 4 (66.7) 1 (29) 
 Grades III-IV 7(33.3) 0 (0) 2 (33.3) 5 (24) 
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6.2.2 CD161+CD4+ T cells are increased in the peripheral blood of 
patients with steroid-refractory aGvHD 
To assess ifCD161+CD4+ T cells are associated with steroid-refractory aGvHD, I 
measured the expression of CD161 on CD4+T cells in PBMC samples from patients 
with steroid-refractory and steroid-responsive aGvHD and in those without GvHD 
directly ex vivo. Because of inter-individual variability in CD4+CD161+ percentage, the 
fold increase in CD161+CD4+ T cells was measured before and after initiation of 
aGvHD therapy with corticosteroids. This was calculated by dividing the frequencies 
of CD161+CD4+ T cells in PBMC samples after  treatment with steroids by the their 
frequencies before treatment.   
 
Patients with SRf aGvHD had significantly higher frequencies of CD161+CD4+ T cells 
after steroid treatment (30.4% ± 2.2% vs. 17.2% ± 2%before steroid therapy, p= 
0.004)(Figure 6.1A). In contrast, the frequency of CD161+CD4+ T cells was not 
significantly different before and after steroid therapy in patients with steroid-
responsive aGvHD (17.9% ± 1.3 vs.17.5% ± 0.4 p= 0.8).Following steroid therapy, 
patients with SRf aGvHD had significantly higher frequencies of CD4+CD161+T cells, 
presented as fold increase, compared to no GvHD patients (1.8 ± 0.23 vs. 1.1 ± 0.07, 
p= 0.002)and SRs aGvHD patients (1.8 ± 0.23 vs. 0.55 ± 0.38, p= 0.02). Moreover, 
the frequencies of CD161+CD4+ T cells was not significantly different in GvHD 
patients who responded to steroid therapy compared to patients with no GvHD (fold 
increase 0.55 ± 0.38 vs. 1.1 ± 0.07, p=ns)(Figure 6.1B). 
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Figure ‎6.1: Change in the frequency of CD161+CD4+ T cells post-transplant. A, 
Scatter plot showing the increase in the frequencies of CD4+ CD161+ T cell in steroid-
refractory aGvHD patients after steroid treatment(n=4)B, Bar chart comparing the fold 
increase in CD161+CD4+ T cells in patients with steroid-responsive(n=3), steroid-
refractory(n=4) and no GvHD (n=8). Fold increase was calculated by dividing 
CD4+CD161+ before and after GvHD occurrence (steroid-treatment). Results 
presented as mean ± SEM. Student t-test and one way ANOVA were used. 
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6.2.3 The expandedCD161+CD4+ T cells in patients with aGvHD have a 
Th17 phenotype 
 
In chapter 4I showed that CD161+CD4+ T cells that resist the in vitro lymphocytotoxic 
effect of dexamethasone have a Th17 phenotype. Therefore, I sought to examine the 
frequencies of IL-17-producing CD4+CD161+cells in patients with aGvHD.  
 
In keeping with the in vitro data, I found that CD4+CD161+IL-17+T cell frequencies 
increased in patients with SRf aGvHD (as assessed by fold increase in 
CD4+CD161+IL-17+ T cells following treatment) compared to patients with no GvHD 
and SRs GvHD patients (fold increase 1.7 ± 0.9 vs. 1.15 ± 0.15 and 0.4 ± 0.3, p= 0.4 
and 0.4, respectively), although the difference did not reach statistical significance 
(Figure 6.2). 
 
 
 
 Abdullah S. Alsuliman  PhD Thesis, 2013 
 
153 
 
Figure ‎6.2:Percentage of CD4+CD161+IL-17+ T cells post-transplant. Bar chart 
comparing the fold increase in CD4
+
CD161
+
IL-17
+
 T cells in patients with steroid-
responsive(n=3), steroid-refractory(n=4) and no GvHD patients (n=8). Fold increase was 
calculated by dividing the frequencies of CD4
+
CD161
+
IL-17
+
 after GvHD occurrence 
(steroid-treated) by theirs before. Results presented as mean ± SEM. 
 
 
 
 
 
 
 
 
 
 
No GvHD SRf GvHD SRs GvHD
0
1
2
3
ns
nsns
F
o
ld
 i
n
c
re
a
s
e
 i
n
C
D
4
+
C
D
1
6
1
+
 I
L
-1
7
+
 Abdullah S. Alsuliman  PhD Thesis, 2013 
 
154 
6.2.4 IFNγ-producingCD161+CD4+ T cells are not increased in patients 
with steroid-responsive or steroid-refractory GvHD 
 
 Previous data (section 4.2.3) demonstrated that in vitro exposure to steroid 
(dexamethasone) has minimal effect on IFNγ production by CD4+CD161+ T cells. For 
this reason, I evaluated the IFNγ production before and after GvHD onset and steroid 
therapy.  
 
As seen previously in the in-vitro experiments, exposure to steroids in both SRs as 
well as SRf aGvHD patients did not have a significant impact onIFNγ-
producingCD4+CD161+cellswhen compared with patients with no GvHD (fold 
increase 0.87 ± 0.11 and 1.02 ± 0.59 vs. 1.5 ± 0.46 , p=0.4)  . Furthermore, unlike IL-
17, there was no difference in IFNγ production between SRf and SRs GvHD 
patients(p= 0.9) (Figure 6.3). 
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Figure ‎6.3:Percentage of CD4+CD161+IFNγ+ T cells post-transplant. Bar chart 
comparing the fold increase in CD4
+
CD161
+IFNγ+ T cells in patients with steroid-
responsive(n=3), steroid-refractory(n=4) and no GvHD patients (n=8). Fold increase was 
calculated by dividing CD4
+
CD161
+IFNγ+ before and after GvHD occurrence (steroid-
treated). Results presented as mean ± SEM. 
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6.2.5 Corticosteroid therapy is associated with a significant reduction in 
CD4+Foxp3+T cells in vivo 
 
Next, I sought to examine if treatment with corticosteroids could disturb the balance 
between T cell subsets, especially by suppressing regulatory T cells (Foxp3+). Thus, I 
compared the frequencies of CD4+Foxp3+ T cells pre- and post- steroid intervention. 
 
I calculated the ratio of CD4+Foxp3+ T cells in patients with aGvHD by dividing their 
frequencies after treatment with corticosteroids by frequencies before treatment. I 
observed a significant reduction in CD4+Foxp3+ T cells frequencies, presented as fold 
increase, following treatment with steroids both in patients with SRs and SRf GvHD 
compared to pre-GvHD therapy (fold increase 0.58 ± 0.16 and 0.67 ± 0.11, 
respectively) (Figure 6.4 A). This suggests that corticosteroids induce apoptosis in 
CD4+Foxp3+ T cells. Of note, CD4+Foxp3+ T cells were almost two fold higher in 
patients with no GvHD compared to patients with SRs and SRf aGvHD(fold increase 
1.8 ± 0.43 vs. 0.6 ± 0.08,p= 0.026) (Figure 6.4 B).  
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Figure ‎6.6: :Percentage of regulatory T cells post-transplant. A, Bar chart comparing the 
fold increase in CD4
+
Foxp3
+
 T cells in patients with steroid-responsive(n=3),steroid-
refractory(n=4)and patients with no GvHD (n=8). B, bar chart showing the effect of steroid 
treatment on CD4
+
Foxp3
+
 in presence of no steroid (n=8) and steroid-treated (n=7). Fold 
increase was calculated by dividing CD4
+
 Foxp3
+
 before and after GvHD occurrence (steroid-
treated). Results presented as mean ± SEM. One way ANOVA were used. 
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6.3 Discussion 
In this chapter, I assessed the change in the frequencies of CD161+CD4+, IL-17 
producing and Foxp3+regulatory T cells in acute GvHD patients following steroid 
therapy, and patients with no sign of aGvHD exploring their role in steroid-refractory 
GvHD in vivo. As shown previously with the in vitro data in the previous chapters, I 
here showed that after treatment with corticosteroids, the frequencies of 
CD161+CD4+ T cells significantly increases in patients with steroid-refractory GvHD, 
suggesting that a subset of CD161+CD4+ T cells have the ability to survive 
corticosteroid therapy in vivo. In addition, I have previously(chapter 3) shown that 
the vast majority of CD161+CD4+ T cells fall within theCD25int. Therefore, this finding 
indirectly correlates with data by Lee and colleagues demonstrating the role of 
CD25intCD4+ T cells in steroid-refractory uveitis (Lee et al. 2009a). These data 
propose that CD161 could be a marker for steroid-resistant T cells. 
 
I have also shown here that the increase in the frequencies of CD161+CD4+ T cells in 
patients with steroid-resistant aGvHD was concomitant with an increase in IL-17 
producing T cells. The frequencies of IL-17-producing CD4+ T cells only decreased in 
patients who responded to steroid treatment. This findings further support the in vitro 
experiments carried out in chapter 4 and are in keeping with previously published 
reports, demonstrating the resistance of Th17 cells to steroid treatment(McKinley et 
al. 2008). Collectively, these data suggest that the IL-17-producing CD161+CD4+ T 
cells might contribute to the pathogenesis of steroid-refractory aGvHD.  
 
The fundamental role of regulatory T cells in immune tolerance has been well 
established. In addition, these cells have been shown to play a role in preventing or 
at least ameliorating GvHD symptoms(section 1.5). Their role, however, in steroid-
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refractory GvHD is not well defined. Previous studies in autoimmune models suggest 
that steroids may induce Tregs, although with impaired suppressive activity, 
suggesting that Foxp3 upregulation in these studies might have actually been a sign 
of T cell activation(Prado et al. 2011b). In contrast, in the previous chapters, I 
demonstrated that corticosteroids induce reduction inCD4+Foxp3+ T cell frequencies. 
In keeping with previous data and in contrast to the in vitro experiments in chapter 4, I 
observed in this study that there was no difference in the frequencies of Foxp3+CD4+ 
T cells following steroid treatment between steroid responsive and non-responsive 
aGvHD patients ex-vivo. Although the percentage of regulatory T cells was 
comparable in aGvHD patients, irrespective of their responsiveness to corticosteroids 
treatment, the reduction in the frequencies of Tregs following steroid therapy was 
associated with a concomitant increase in IL-17-producing CD161+CD4+ T cells only 
in patients with steroid-refractory aGvHD. However, the suppressive properties of 
Treg from both patient groups could not be compared in view of the paucity of the 
available samples. Altogether, these data suggest that the imbalance between the 
effector and regulatory T cells; in favour of the effector phenotype, might play a 
significant role in the pathogenesis of steroid-refractory acute GvHD (section 1.4.3) 
supporting the notion that steroids can disturb the balance between Th17 and Tregs.  
 
In summary, the data in this chapter are consistent with the in vitro experiments 
presented in chapter 4.This study is however limited by the small number of 
samples, which preclude a definitive conclusion. Also, the timing for the sample 
collection, especially before GvHD onset, was another obstacle that needs to be 
considered. A larger prospective study is required to establish the role of 
CD4+CD161+IL-17+ T cells as well as their balance with regulatory T cells, in respect 
of frequencies and functions, in steroid-refractory aGvHD. 
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CHAPTER 7. GRAFT TH17 AND REGULATORY T CELL 
CONTENT AND RISK OF ACUTE GVHD POST-
TRANSPLANT 
7.1 Introduction 
Allogeneic stem cell transplantation remains the treatment of choice for a variety of 
haematological disorders. The source of the donor graft and its content are likely to 
play an important role in determining the success of this therapy. Historically, bone 
marrow was the main source of haematopoietic stem cells (HSC). More recently, 
peripheral blood stem cells (PBSC) mobilized with granulocyte-colony stimulating 
factor (G-CSF) has been increasingly used as the source of stem cells for AHSCT, 
due to its ease of procurement and more rapid engraftment. In patients who continue 
to have residual disease following AHSCT or those with persistent mixed chimerism, 
donor lymphocyte infusion (DLI) is used to prevent disease relapse. However, 
mature T cells within the graft as well as DLI might induce undesirable reactions 
such as acute GvHD.  
 
 
The effect of G-CSF mobilization on immune cells has been extensively studied(Abbi 
et al. 2012;Dhedin et al. 2006;Joo, Lee, Won, Lee, Kim, Park, Park, Choi, Choi, & 
Seo 2012;Toh et al. 2009;Vela-Ojeda et al. 2005;Zhao, Xu, Lu, & Huang 
2011).Interestingly, in spite of harbouring ten times more T cells, the incidence of 
acute GvHD after PBSC is similar to BM transplantation(Bensinger et al. 2001), 
although more recent data suggest an increase in the rates of chronic GvHD 
following PBSC transplants(Anasetti et al. 2012). In addition, although it has been 
determined that the regulatory T cell content is lower in G-CSF  
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mobilized graft compared to conventional bone marrow graft, the effect of G-CSF 
mobilization is believed to be immunomodulatory, thereby reducing the risk and 
severity of acute GvHD(Abbi et al. 2012). 
 
Graft versus host disease post-transplantation hampers the success of AHSCT. A 
number of studies have examined the relationship between the cellular content of 
the graft or the DLI product and the risk of aGvHD following AHSCT. T cells have 
been shown to play an indispensable role in the pathogenesis of GvHD. Several 
studies have focused on the importance ofTh17/Treg balance and risk of 
aGvHD(section 1.5).  
 
Data presented in the chapters4 and 5 of this thesis suggest a potential role for Th17 
precursors, CD4+CD161+ T cells, in refractory aGvHD. I showed that CD161+CD4+ T 
cells may play a role in the pathogenesis of steroid-refractory aGvHD through their 
ability to efflux dexamethasone, an ABCB1 transporter substrate.  
 
The objective of this chapter is to examine the T cell content of the donor graft, 
specifically the frequencies of CD4+CD161+ T cells, Th17 and Foxp3+ regulatory T 
cells, the Th17/Treg ratio, and their role in the development of acute GvHD. In 
addition, by comparing T cell content of G-CSF mobilised PBSC graft and DLI (not 
G-CSF mobilised), I will study the effect of G-CSF on the phenotype and function of 
these different T cell subsets. 
 
 
 
 Abdullah S. Alsuliman  PhD Thesis, 2013 
 
162 
7.2 Results 
 
7.2.1 Patients characteristics 
In recipients of allogeneic PBSC, GCSF-mobilised donor grafts(n=24)and donor 
lymphocytes (DLI)(n=20) were cryopreserved and stored in the John Goldman 
centre for cellular therapy at Hammersmith Hospital. All donors and patients gave 
written informed consent for the use of their material for the research study.  
 
To assess the association between the content of GCSF-mobilised donor graft and 
the risk of aGvHD, patients were divided into two groups according to the onset of 
acute GvHD; No acute GvHD (n=17) and acute GvHD (n=7)(Table 7.1). GvHD 
diagnosis and grading was done routinely in transplant clinic using the modified 
Seattle Glucksberg criteria. Patient characteristics are summarised in Table 7.1.  
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Table ‎7.1: Characteristics of stem cell transplantations patients. Patients were sub-
divided into two groups according to acute GvHD occurrence. 
 
 
 
All                        
(N=24)                       
No acute 
GvHD 
(N=17)
 acute 
GvHD (N=7)
number (percent)
Median age in years                
(range)
44.7           
(18-63.4)
47.1          
(18-56.1)
45.3         
(28.3-63.4)
Sex
 Male 15 (62.5) 10 (58.8) 5 (71.4)
 Female 9  (38.5) 7 (41.2) 2 (28.6)
Diagnosis
 Acute leukemia 8 (33.3) 7 (41.2) 1 (14.2)
 Chronic myelogenous leukemia 6 (25) 5 (29.4) 1 (14.2)
 Malignant lymphoma 4 (16.7) 1 (5.9) 3 (42.8)
 Others 6 (25) 4 (23.5) 2 (28.6)
Conditioning regimen
 Myeloablative conditioning 8 (33.3) 2 (11.8) 6 (85.7)
 Reduced intensity conditioning 16 (66.7) 15 (80.2) 1(14.3)
Stem cell donors
 Related 23(95.8) 16 (94.1) 7 (100)
 Unrelated 1 (4.2) 1 (5.9) 0 (0)
HLA Match
 HLA-identical 17 (70.8) 11 (64.7) 6 (85.7)
 HLA-mismatched 7 (29.2) 6 (35.3) 1 (14.3)
Stem cell source
 Bone Marrow 2 (8.3) 2 (11.8) 0 (0)
 Peripheral Blood Stem Cells 22(91.7) 15 (80.2) 7 (100)
GvHD grading
 Grades I-II 2 (8.3) 0 (0) 2 (28.6)
 Grades III-IV 5 (20.8) 0 (0) 5 (71.4)
CMV serology status
 CMV postive 18 (75) 13 (76.4) 5 (71.4)
 CMV negative 6 (25) 4 (23.6) 2 (38.6)
Transplant outcome
Relapse 9 (37.5) 8 (47.1) 1 (14.3)
No relapse 15 (62.5) 9 (52.9) 6 (85.7)
0 0) 
4 ( 00) 
0 (0) 
17 (100) 
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7.2.2 G-CSF effect on the frequencies of CD4+CD161+ T cells, Th17 and 
Foxp3+ T cells. 
 
I first sought to assess the effect of G-CSF on the frequencies of T cell subsets by 
comparing percentages of CD4+CD161+ T cells, Th17 and Tregs in G-CSF-
mobilized grafts and the DLI samples. There was no significant difference in the 
frequencies of Th17 cells in G-CSF mobilised grafts compared to DLI samples 
(0.68% ± 0.1 vs. 0.69% ± 0.09, p=0.96) (Figure 7.1A). Similarly, G-CSF mobilization 
did not have an impact on the frequencies of CD4+Foxp3+ T cells(4.3% ± 0.25 vs. 
3.9% ± 0.28, p=0.4) (Figure 7.1C), although naïve Tregs (CD45RA+CCR7+) were 
more abundant in G-CSF mobilised grafts compared to DLI (33.4% ± 3.5 vs. 23.1%± 
3, p=0.035) (Figure 7.1D). On the other hand, CD161+CD4+ T cells were 
significantly lower in G-CSF mobilised grafts compared to DLI samples (4.4% ± 0.56 
vs. 6.5% ± 1.1, p= 0.04) (Figure 7.1B) .These data suggest that G-CSF skews the T 
cell composition of the graft to a more immunomodulatory phenotype by increasing 
the proportion of naïve Tregs and reducing the frequencies of CD161+ CD4+T cells. 
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Figure ‎7.1:Scattered plots showing the differences in the proportions of T cell 
subsets in G-CSF mobilised grafts compared to DLI (without G-CSF). A, proportion 
ofCD4
+
 IL-17
+
 T cells  B, frequency of CD4
+
161
+
T cells. C, Frequency 
CD4
+
Foxp3
+
regulatory T cells. and D, Frequency of naïve Foxp3
+
 Treg. Data represent 
the mean ± SEM. Student t-test was used. 
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7.2.3 Frequencies of CD4+CD161+ T cells, Th17 and regulatory T cells in 
the donor grafts do not predict for risk of acute GvHD post-transplant 
 
A number of studies suggest a role for Th17 cells in the pathogenesis of acute 
GvHD; CD4+CD161+CCR6+ T cells, the precursor for Th17 cells, are enriched in the 
gastrointestinal tract biopsy of aGvHD patients(Bossard et al. 2012). In contrast, 
regulatory T cells have been shown to protect against GvHD(section 1.5). 
Therefore, I sought to evaluate the frequencies of these subsets in the donor graft 
and correlate their frequencies with the risk of aGvHD.  
 
There was no significant difference in the frequencies of IL-17-producing CD4+ T 
cells (Th17) (0.55% ± 0.12% vs. 0.74% ± 0.12%, p= 0.39)(Figure 7.2A)or 
CD161+CD4+ T cells(4.9% ± 1.0% vs. 4.2% ± 0.7%, p=0.5)in grafts transfused into 
patients with or without aGvHD (Figure 7.2B). Similarly, there was no significant 
difference in the frequencies of CD4+Foxp3+ regulatory T cells, both total and naïve, 
in patients with or without aGvHD; p= 0.3 and p=0.8, respectively (Figure 7.2C and 
D).   
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Figure ‎7.2:Scatter plots comparing frequencies of T cell subsets in donor grafts of 
patient with and without acute GvHD. A, Frequencies ofCD4
+
 IL-17
+
 T cells  B, 
Frequencies of CD4
+
161
+
T cells. C, Frequencies of CD4
+
Foxp3
+
regulatory T cells and 
D, Frequencies of naïve CD4
+
Foxp3
+
 Treg. Data represent the mean ± SEM. 
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7.2.4 Ratios of CD4+CD161+ T cells/Tregs and Th17/Tregs do not predict 
for risk of aGvHD. 
 
A number of studies have suggested that the ratio of Treg/Th17 cells, rather than the 
frequencies of these T cell subsets, is predictive for risk of aGvHD(Dander et al. 
2009;Ratajczak et al. 2010). Thus, the ratios of Th17/Tregs and CD4+CD161+ T 
cells/Tregs in the donor graft and the risk of aGvHD were assessed. I found no 
significant difference in the Treg: Th17 ratio (11.3 ± 2.5 vs. 10.3 ± 1.7, p=0.8)or 
Treg/CD161+CD4+ T cell ratio in patients with or without aGvHD (1.6 ± 0.41 vs.1.5 ± 
0.62), p=0.9; (Figure 7.3) 
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Figure ‎7.3:Scatter plots examining Th17/Tregs and CD4+CD161+ T cells/Tregs 
ratios in the donor graft and the risk of aGvHD. Ratios were calculated by dividing 
the frequencies of Th17 cells by Tregs and CD161
+
CD4
+
 T cells by Tregs. A, Treg:Th17 
ratio in patients with or without aGvHD. B, Ratio of Treg/CD4
+
161
+
 T cells in patients 
with or without aGvHD. Data represent the mean ± SEM. Student t-test was used. 
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7.3 Discussion 
In this study, the association between Th17, regulatory T cells and CD4+CD161+ T 
cells, and the risk of aGvHD was investigated. I used cryopreserved pilot samples of 
donor grafts that were infused into patients undergoing allogeneic G-CSF mobilized 
grafts. I also assessed the impact of G-CSF on T cell subsets, by comparingTh17, 
Treg and CD161+CD4+ T cell frequencies in G-CSF mobilised donor grafts and DLI 
samples.  
 
A number of studies suggest that G-CSF may exert an immunomodulatory effect on 
T cell subsets in the graft(Toh et al. 2009;Vela-Ojeda et al. 2005;Vela-Ojeda et al. 
2010;Zhao, Xu, Lu, & Huang 2011). In support of these data, Toh et al recently 
demonstrated that whereas G-CSF induces Treg-related genes such as TGF-β, it 
reduces the expression of the Th17 transcriptional factor gene, RORγt. The 
observed changes in the molecular profile of T cells in response to G-CSF were 
associated with a reduction in Th17 and increase in regulatory T cells. The 
observation that G-CSF can ameliorate the symptoms of acute GvHD is thought to 
be at least partly mediated through inhibition of Th17 differentiation(Joo et al. 
2012).However, in this study I did not observe an impact of G-CSF mobilisation on 
the frequencies of IL-17-producing CD4+ T cells. Furthermore, I did not observe an 
association between the Th17 content in the graft and the risk of aGvHD. However, 
our observation that G-CSF mobilisation reduces theCD161+CD4+ T cell content in 
the donor graft further supports an immunomodulatory effect of G-CSF on T cell 
subsets. 
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Several studies have shown a crucial role for regulatory T cells in immune tolerance 
and protection from GvHD in mice and human (section 1.5). Indeed, in the HSCT 
setting, Rezvani et al. showed that the higher Foxp3+ T cell content in the donor graft 
is associated with a lower risk of aGvHD(Rezvani et al. 2006). Moreover, the 
balance of Treg and Th17 cells has been shown to play a role in the pathogenesis of 
aGvHD(Ratajczak et al. 2010). I found that naïve Foxp3+ T cells are significantly 
higher in G-CSF mobilised donor graft; and this data is in agreement with previous 
reports that CD62L+naïve regulatory T cells are more protective than CD62L- 
counterparts(Ermann et al. 2005;Vela-Ojeda et al. 2010). 
 
Under normal circumstances the ratio between T cell subsets are tightly controlled. 
However, disruption of this balance may result in autoimmune disorders or 
acceleration of inflammatory reactions such as GvHD. Disturbances in the balance 
of regulatory T cells and Th17 cells has been suggested to a play a role in the 
pathogenesis of GvHD(Ratajczak et al. 2010). In the present study however, I found 
no significant differences in the ratios of Treg/Th17 and Treg/CD161+CD4+ T cells in 
the donor graft of patients with or without aGvHD.  
 
Collectively, our findings that G-CSF mobilisation reduces theCD161+CD4+ T cell 
content in the donor graft and increases naïve Tregs support an immunomodulatory 
effect of G-CSF on the donor graft. However, the low number of available samples 
and the retrospective nature of the analysis significantly limit this study. I plan to 
validate these data in a larger prospective study. 
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CHAPTER 8. GENERAL DISCUSSION AND FUTURE PLANS 
8.1 General discussion 
 
Allogeneic stem cell transplantation (AHSCT) is the only successful therapeutic 
option for a number of haematological malignancies. Eradicating the residual 
leukemic cells and replenishing the recipient‟s haematopoietic stem cell compartment 
and cellular immunity are the main actions of this modality. However, the ultimate 
success of AHSCT is hindered by a number of complications including GvHD, 
initiated by the interaction between the graft cellular components, mainly T 
lymphocytes, and the recipient‟s tissue antigens and cytokine milieu. Nonetheless, 
the cellular content of the graft in AHSCT controls to a great extent the ultimate 
outcome of the procedure. Indeed, the presence of T cells in the graft determines 
GVL and immune reconstitution as well as the risk of GvHD. Compelling evidence 
suggests that the interplay between T cell subsets infused within the graft, including 
Th1, Th17 and regulatory T cells, is a major factor influencing the outcome of 
AHSCT. Therefore, maintaining the balance between these subsets is likely to be 
paramount for the success of this treatment.  
The specific aims of this thesis were: 
1. To evaluate the existence of stem-like memory T cells with drug effluxing 
ability in the peripheral blood of healthy controls and patients with AML. 
2. To examine the functional phenotype of drug effluxing CD4+ and CD8+ T 
cells, including their Th1 and Th17 profile. 
3. To examine mechanisms of steroid-refractory GvHD by assessing the in 
vitro and in vivo resistance of T cell subsets (Th1, Th17 and Tregs) to 
corticosteroids as well as calcineurin and mTOR inhibitors. 
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4. To evaluate the impact of donor T cell subsets (Th1, Th2, Th17 and 
Tregs) infused with the graft on risk of GvHD. 
 
The achievements of this thesis can be summarised as follows: In chapter 3, I 
demonstrated the existence of a sub-population of CD4+ T lymphocytes with stem 
cell-like properties. I demonstrated that this subset of CD4+ T cells can be defined 
phenotypically by co-expression of CD161, and have the ability to rapidly efflux 
rhodamine through the MDR pump. Interfering with the ABC transporters using 
specific chemical inhibitors such as CsA abrogated the effluxing ability of these cells. 
Furthermore, I showed that drug-effluxing CD161+CD4+ T cells are enriched within 
the viral-specific Th1 repertoire and survive lymphocytotoxic chemotherapy, such as 
daunorubicin, through their ABCB1 pump effluxing ability. These data are in keeping 
with work by Turtle and colleagues (Turtle et al. 2009)which showed the existence of 
a similar subset of stem-like memory T cells in CD8 compartment, capable of rapidly 
effluxing cytotoxic chemotherapeutic agents through the ABCB1 transporter complex. 
These cells were found to possess stem-like characteristics, including expression of 
the anti-apoptotic molecules; Bcl-2 and Bcl-xl, in addition to their quiescence under 
physiological conditions.  
 
In chapter 4, I explored whether drug-effluxing CD161+CD4+ T cells may also play a 
role in the pathogenesis of GvHD and whether they exhibit in vitro resistance to the 
lymphocytotoxic and immunosuppressive effects of corticosteroids and calcineurin 
and mTOR inhibitors. Immunosuppressive drugs such as tacrolimus and in some 
centres, rapamycin, are used as prophylaxis to minimize the risk of acute and chronic 
GvHD. In addition, upon the occurrence of GvHD other interventions (primarily 
corticosteroids) are used to treat the disease. Interestingly, some of the drugs used in  
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GvHD prophylaxis and treatment, including corticosteroids, tacrolimus and 
rapamycin, are substrates of the ABCB1 transporter complex(Schinkel & Jonker 
2003).  In chapter 4, I indirectly evaluated the effect of dexamethasone, tacrolimus 
and rapamycinon the survival, proliferation and effector function of the drug-effluxing 
CD4+CD161+ T cells. I showed thatCD161+CD4+T cells stimulated in vitro with anti-
CD3/CD28 beads have the ability to resist the immunosuppressive and 
lymphocytotoxic effects of tacrolimus and dexamethasone. Additionally, using a 
CFSE proliferation assay, I demonstrated that CD161+CD4+ T cells proliferate 
preferentially, suggesting that this subset of CD4+ T cells may have an inherent 
resistance to the immune suppressive effect of these drugs. These results are in 
keeping with a study by Lee and colleagues, reporting the existence of subset of 
CD4+T cells with resistance to steroids. These cells were characterized by the 
intermediate expression of IL-2Rα (CD25)(Lee et al. 2007). Similarly, I showed that 
the vast majority of CD161+CD4+ T cells also displayed intermediate expression of 
CD25. The promising reports of clinical response to treatment with Daclizumab, a 
mAb against alpha subunit of the IL-2R (anti-CD25) in steroid-refractory GvHD 
(reviewed in (Dignan et al. 2012)), may be partially attributable to the extermination of 
CD4+CD25int CD161+ T cells. However, the fact that regulatory T cells share CD25 
expression with these cells might hinder the usefulness of this approach. Therefore, 
specific targeting of these cells using a monoclonal antibody to CD161,for instance, 
may potentially facilitate eradication of steroid-resistant subsets while sparing 
regulatory T cells. I showed that the preferential survival and expansion 
ofCD161+CD4+ T cells in the presence of dexamethasone is concomitant with a 
dramatic induction in IL-17, but not IFNγ production. The role of Th17 cells in the 
pathogenesis of GvHD is controversial although Th17 cells have been shown to 
mediate resistance to steroids in airway inflammation(McKinley et al. 2008). 
 
 Abdullah S. Alsuliman  PhD Thesis, 2013 
 
175 
Interestingly, I found that CD4+Foxp3+ T cells are highly susceptible to the 
lymphocytotoxic effect of dexamethasone in vitro. Collectively, these data suggest 
that CD161+CD4+ T cells may play a role in steroid-refractory GvHD through their 
ability to preferentially survive the cytotoxic effect of steroids, accompanied with an 
induction in their pro-inflammatory functions (Th17). In addition, the increased 
susceptibility of CD4+Foxp3+ T cells to treatment with steroids may further skew the 
Th17/Treg ratio and contribute to the pathogenesis of GvHD.  
 
I then explored the combination of ABCB transporter inhibitors and 
immunosuppressive drugs and their effect on CD4+CD161+ Th17 cells. Expression of 
multi-drug transporters e.g. ABCB1, is a mechanism through which CD161+CD4+ T 
cells efflux cytotoxic drugs that are ABCB1 substrates.  Inhibitors of the ABCB1 
transporter, which prevent the efflux of its substrate, have been widely used in 
combination with cytotoxic drugs to enhance their activity. This approach is already 
exploited in cancer therapy(Walter et al. 2004). Here, I showed that the addition of 
inhibitors for both ABCB1 and ABCC1 (vinblastine) to dexamethasone increased the 
lymphocytotoxic effect of dexamethasone on CD4+CD161+ Th17 cells. These data 
support a role for the use of ABCB1 transporter inhibitors in combination with 
dexamethasone to overcome the resistance of CD161+CD4+ T cells to steroids. 
 
In chapter 5, I explored the impact of combinations of dexamethasone with tacrolimus 
or rapamycin on CD161+CD4+ T cells in vitro. I showed that combining tacrolimus 
with dexamethasone or with rapamycin significantly reduces IL-17 production by 
CD4+CD161+ T cells. Prospective and randomised clinical studies are now needed to 
evaluate the in vivo safety and efficacy of these drug combinations in the prevention 
and treatment of GvHD. 
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In Chapter 6, I explored the role of CD161+CD4+ T cells in steroid-refractory GvHD in 
vivo. I studied the frequency and functionality of CD161+CD4+ T cells in patients with 
aGvHD before and after steroid therapy. Interestingly, I found that the frequency of 
CD161+CD4+ T cells increased significantly in patients with steroid-refractory GvHD 
compared to patients with steroid-responsive GvHD or those without evidence of 
GvHD patients. In keeping with my in vitro data (chapter 4), steroid treatment 
resulted in a significant reduction in the number of  regulatory T cells, irrespective of 
treatment outcome. Altogether, these results suggest that steroid-refractory GvHD 
might be partly caused by induction of CD161+CD4+ T cells and the concurrent 
reduction in regulatory T cells in response to steroid treatment. However, these data 
will need further validation using a confirmatory and larger cohort of patients.  
 
Finally, I explored the impact of donor T cell content on risk of GvHD; specifically 
asking the following questions: 1) what is the impact of G-CSF on the phenotype and 
function of T cell subsets in the graft and 2) Does the frequency of Th17 and Tregs in 
the donor graft predict for risk of aGvHD post AHSCT? Interestingly, I observed a 
shift to a more immunomodulatory phenotype, with higher naïve regulatory T cells 
and lower CD161+CD4+ T cell percentages in G-CSF-mobilised grafts compared to 
DLI samples (non-G-CSF mobilised).  However, I did not observe a correlation 
between CD4+CD161+, Th17 and Treg content in the graft and the risk of GvHD 
occurrence. However, these data are limited due to the small number of samples 
analysed and the retrospective nature of the study. 
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Collectively, the results presented in this thesis show the existence of a memory 
subset of CD161+CD4+ T cells with stem cell-like properties. The enrichment of 
antigen specific memory T cells within this subset might have significant implications 
for the development of the next generation of T cell based immunotherapies against 
pathogens and tumours. Moreover, CD161+CD4+ T cells showed a selective survival 
and proliferation advantage in the presence of steroids with skewing towards a Th17 
phenotype and concomitant reduction in CD4+Foxp3+ regulatory T cells. These 
changes were partially reversed by combining steroids with other immunosuppressive 
drugs such as calcineurin and mTOR inhibitors and selective inhibitors of ABC 
transporters. Altogether, these data might help in developing a graft engineering 
approach aimed at controlling the expansion of these cells and maintaining the 
balance between the effector and regulatory arms of the cellular immune response.  
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8.2 Future plans 
I have shown the existence of stem cell-like memory CD4+CD161+ Th1 and Th17 
cells with rapid drug-effluxing capacity. I propose to characterize these cells more 
comprehensively. Specifically, I propose to sort purify the rapidly-effluxing 
CD4+CD161+ Rh123- and the non-effluxing CD4+CD161+ Rh123+ T cells to compare 
their molecular signature by gene expression profiling. I would like to specifically 
study the differential expression of ATP-binding cassette B1 (ABCB1), anti-apoptotic 
molecules (Bcl-2 and Bcl-xl) and transcription factors.  
 
To further investigate the preferential enrichment of antigen specific CD4+ T cells 
including CMV, EBV and influenza within the sorted Rh123-effluxing population, I 
propose to optimise assays of HLA Class II tetramer staining, to allow sort-purification 
of viral-specific CD4+ T cells within the CD161+ T cell fraction. Using a humanized 
mouse model of CMV infection(Berges and Rowan 2011;Smith et al. 2010), I will 
compare the ability of the adoptively transferred CD161+ and CD161- CD4+T cells to 
protect against viral infection and their role in providing long-term immunity against 
secondary viral challenge. This model will also allow me to examine the resistance of 
the adoptively transferred sort-purified viral-specific CD161+ CD4+ T cells to cytotoxic 
drugs including chemotherapeutic agents and steroids. These data will be especially 
important for the development of clinical protocols of adoptive therapy in patients with 
viral reactivation (e.g. CMV) during corticosteroid therapy for aGvHD, where 
resistance of the adoptively transferred viral-specific T cells to the lymphocytotoxic 
effect of the steroids will be highly desirable. 
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To further investigate the role of “drug-effluxing” CD161+CD4+ T cells in the 
pathogenesis of steroid-refractory GvHD, I propose a prospective study to compare 
the frequencies of CD4+CD161+ Th17 cells in patients with steroid-refractory and 
steroid-responsive GvHD and those without GvHD. The aim will be to validate the ex 
vivo findings presented in chapter 6, confirming a role of CD161+CD4+ T cells in the 
pathogenesis of steroid-refractory GvHD. I would also like to assess the effect of 
second line interventions employed for the treatment of steroid-refractory GvHD on 
CD161+CD4+ T cell frequencies, and the reciprocal balance between Th17 and 
regulatory T cells. 
 
Using a Human/Mouse xenogeneic SCID mouse model I will study the contribution of 
CD161+CD4+ T cells to the pathogenesis of GvHD by infusing sort-purified 
CD161+CD4+or CD161-CD4+T cells along with the graft and I will then evaluate the 
severity of ensuing GvHD in the two animal groups and their response to steroid 
treatment. These data will have important implications in the development of novel 
strategies to prevent and manage steroid-refractory GvHD, including approaches to 
graft engineering and selective depletion of CD161 expressing T cells, as well as 
development of monoclonal antibodies to target and deplete CD161 expressing T 
cells in patients with steroid-refractory GvHD. 
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